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Abstract
Characterization of genetic variation underlying complex phenotypes is incomplete yet
critical to understanding mutational mechanisms and phenotypes. Heterozygote Instability
(HI) is a new, poorly understood source of mutations needing models for mechanistic
study. Two models ideal for characterizing HI-associated mutational mechanisms are
outbred mice and mouse basal cell carcinoma (BCC). Both have discontinuous landscapes
of heterozygosity essential to assess HI-induced mutations. Here, heterozygosity and
copy number variants (CNVs) in two outbred mouse stocks are characterized with 1690,
and 3935 autosomal CNVs detected. A positive correlation exists between chromosomal
heterozygosity and CNV occurrence (R2 = 0.14 and 0.09), and 41 and 22% of CNVs
co-localized with heterozygosity. Genetic variation in human BCC is documented to
target characterization in mouse BCC toward filling an identified knowledge gap. An
outbred BCC mouse model permits HI hypothesis testing in contexts of meiosis, mitosis,
replication, and recombination in gametes, stem cells, and cancer cells.

Keywords: Genetic variants, germline mutations, somatic mutations, outbred mice,
basal cell carcinoma, mouse models, Heterozygote Instability, mutation landscape, single
nucleotide polymorphisms, copy number variants
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Summary for Lay Audience
Mouse models are helpful to study complicated or elusive human genetic phenomena.
DNA sequence differences are referred to as genetic variants and include differences in
single bases and deletions or duplications of larger regions of sequences, called copy
number variants (CNV). Genetic variants contribute to diseases and complex traits that
have both genetic and environmental factors. Typically the chromosomes inherited from
each parent are not identical, with the inheritance of single-base differences at the same
location, referred to as heterozygosity. Recent research discovered that localized regions
of heterozygosity increased mutations in plants. However, this phenomenon, known as
Heterozygote Instability (HI), has yet to be investigated in mammals. This thesis explores
HI in two mouse models of high heterozygosity by analyzing inherited variation in outbred
mice and acquired variation in mouse models of skin cancer, basal cell carcinoma (BCC).
Researchers have bred outbred mice to mimic the high genetic diversity found among
humans. However, the genetic variants in their DNA are less characterized than the
currently favoured laboratory inbred mouse, precluding exploration of mechanisms of
mutation associated with heterozygosity. In the outbred mouse stocks, heterozygosity and
CNVs must be characterized to study their co-localization and assess if regional variation
in heterozygosity is associated with CNVs. This thesis characterized heterozygosity
and CNVs in two stocks of outbred mice and detected CNVs associated with regional
variation in heterozygosity. Additionally, the high heterozygosity in human skin and
human BCC permits the study of mutagenesis in the context of HI. A systematic review
of studies researching mutations in human tumors and BCC mouse models highlighted the
striking lack of mutations characterized in mouse models of BCC. This disparity limits
understanding of BCC mouse models, their traits and their applicability to study HI and
complex traits. Experimental designs were presented to assess and detect the extent of
genetic variants to determine whether mouse models are good mimics of human BCC.
iii

These mouse models of high genetic variation offer a means to elucidate the mechanisms
of mutation that contribute to an elusive and complicated form of genomic instability, HI,
relevant to complex human traits, including cancer formation.
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Chapter 1.
Introduction
1.1

Genome variation

Genetic variants are responsible for differences within and between populations and can
contribute to phenotypic diversity. Examples include diversity in gene regulation, complex
phenotypes, varied clinical outcomes, varied responses to drugs, and diseases, including
cancer, Alzheimer’s disease, and schizophrenia [1–3]. A complex phenotype results from
the combined interactions between multiple genetic variants and environmental factors.
In comparison, a single gene disorder results from a small number of variants with large
effect sizes [4]. A difference in a DNA sequence at a given location or gene between
individuals is known as a genetic variant. Genetic variants consist of a combination of
polymorphisms and mutations. Polymorphisms are differences between individuals in
single nucleotides present in greater than 1% of the population, which may or may not
affect phenotype. In contrast, mutations have occurrences below this percentage and can
have more profound effects [1, 5].
Mutations can either arise in germ cells that result in inherited mutations in the
constitutive zygote genome or arise post-zygotically as acquired mutations in somatic and
germ cells. Germline mutations occur in an individual’s gametes, and they are passed on
to the next generation. In contrast, somatic mutations are present in other cells of the
body and are not inherited [6]. A de novo mutation is the first occurrence of a mutation,
and it can either be a germline or somatic mutation, or both, depending on when and
where the mutation occurs [6, 7]. If the mutation occurs before fertilization, in either
the egg cell or the sperm cell as it is passed on to the offspring, it is a de novo germline
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mutation. If the mutation occurs later in development in cells other than the gametes, it
is a de novo somatic mutation [6, 7]. Mutations can be categorized as point mutations,
which are changes at one nucleotide, or structural variants, including insertions, deletions,
inversions, duplications, or translocations [6]. To better understand how genetic variants
affect complex phenotypes, mutational mechanisms associated with genetic variation must
also be defined. The mutation rate is not constant along the chromosomal sequence,
and while multiple mechanisms are known, all mechanisms underlying this are not fully
understood [8]. Variation in mutation rate can be sequence-dependent, and a novel
sequence-dependent mutational mechanism was identified at heterozygous locations across
the genome.

1.2

Heterozygote instability

Yang et al (2015), for the first time, demonstrated a connection between increased
heterozygosity and elevated mutation rates. Heterozygosity is defined as the occurrence of
two different alleles at the same location between homologous chromosomes, and mutation
rate is defined as the number of de novo mutations that occur in an individual or gene over
time. The connection between heterozygosity and de novo mutations highlighted a new
potential mechanism contributing to spontaneous mutagenesis. Through investigating
single nucleotide polymorphisms (SNPs) and small insertions and deletions in Arabidopsis
[9], Yang et al (2015) found that during meiosis, plants with high levels of heterozygosity
have higher mutation rates than plants with lower levels. The mutations were occurring in
close proximity to heterozygous loci and crossover events [9]. This phenomenon was tested
in peach plants by crossing either intra-species plants or inter-species plants, and Xie et
al (2016) found that hybrid plants had higher mutation rates, comparable to findings in
Arabidopsis [10]. Both studies suggest this phenomenon occurs during meiosis. It is not
known if this is germ cell-specific or also operative in somatic cells. HI has not been studied
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in situations of high cell division, for example, during development or carcinogenesis.
The hypothesis that heterozygosity contributes to de novo mutagenesis is called the
Heterozygote Instability (HI) hypothesis [11]. HI has been computationally demonstrated
with local heterozygosity and microsatellites in 1163 human genome sequences from the
1000 Genome Project [12] but has yet to be explored with insertions and deletions or larger
structural variants. There are three tenets of the Heterozygous Instability hypothesis.
First, there must be heterozygosity present in the genome. Second, the heterozygosity
must be non-randomly distributed throughout the genome, with clusters of heterozygosity
separated by clusters of homozygosity. Third, there must be de novo copy number variants
(CNVs) or other structural variants present in the genome.
The phenomenon of heterozygosity increasing de novo mutations observed in Arabidopsis and again in peach plants has not yet been reported in mammals. Point mutations,
small insertions and deletions, and larger structural variants (duplications and deletions of
at least 500 base pairs), such as CNVs occur in the genomes of both plants and mammals
[13–16]. Other similar mutational mechanisms exist in plants and mammals, including an
increased level of mutations at repetitive DNA sequence and near transposable elements
[16], and UV-induced mutagenesis [14]. Comparable mutations and mechanisms indicate
that similar mutational mechanisms, like HI, may occur in mammals and should be further
studied to shed light on the mechanisms operating. Additionally, while evidence suggests
HI operates during meiosis [9, 10], no research has been performed to analyze HI during
mitosis in somatic cells. Thus, two opportunities to further study HI are in the genome
of mammals, looking at both germ and somatic cells.
This thesis evaluates two mouse models of high genetic variation, outbred mice and
mouse models of basal cell carcinoma for the study of HI in germ and somatic cells,
respectively, and provides novel data and workflows towards the characterization of both
models. Characterization of the landscape or spatial distribution of genetic variation in this
thesis is defined as the detection, examination and documentation of heterozygous SNP
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loci or heterozygosity and CNVs. Characterization of heterozygosity at SNP loci involves
detection of the genomic location of heterozygous SNP loci and areas of localized high
levels of heterozygosity called clusters, and areas of localized high levels of homozygosity
called deserts. Additionally, CNVs are characterized through many attributes, including
location, length, copy number state, recurrence in multiple samples, and genic content.
After characterizing the SNP landscape and the CNV landscape, the two landscapes
can be analyzed simultaneously to see where they occur across the genome and if the
occurrence of CNVs is proximal to clusters of heterozygosity.

1.3
1.3.1

Genetic variants in complex phenotypes
Functionally relevant mutations

Genetic variants occur throughout the genome. To better understand complex phenotypes
and diseases, research focuses on characterizing and understanding the mutations that have
functional implications. Point mutations can be silent, nonsense, or missense mutations,
with silent mutations not causing a change in an amino acid due to redundancy in the
genetic code. The redundancy means most amino acids are specified by more than
one codon, allowing for a nucleotide variation without changing the encoded amino
acid. Nonsense mutations replace the original amino acid with a premature stop codon,
causing a truncated protein. Missense mutations lead to replacing the original amino
acid with a different amino acid, where this can be conserved or non-conserved [1, 5, 6].
Conservative mutations occur when the substituted amino acid has the same properties
as the original amino acid, either hydrophobic, hydrophilic, polar, non-polar, or charged.
Non-conservative mutations occur when the substituted amino acid does not have the
same properties as the original amino acid [6]. Silent and conservative mutations will not
usually contribute to a change in phenotype and thus are functionally silent, whereas
nonsense, missense, and non-conservative mutations all potentially affect function, either
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directly or indirectly.
Structural variants can cause frameshift mutations. Frameshift mutations are due
to insertions or deletions of nucleotides that disrupt the reading frame of a gene, consequently changing the amino acids downstream of the mutation [6]. Types of structural
variants include duplications, deletions, copy number variants, insertions, transversions
and translocations. When structural variants encompass or overlap genes, they may
affect gene dosage and thus have possible functional impacts due to either an increase or
decrease in the amount of protein produced [17]. Mutation hotspots are genomic locations
where mutations occur more frequently than expected in multiple individuals or within
specific cancer types, referred to as recurrent mutations [5, 18]. Mutation hotspots are
relevant to structural mutations and further study of the varied mutation rate along the
chromosomal sequence.
For a mutation to affect a phenotype, termed a functional variant, the mutation must
alter the translated protein product’s ability to function correctly, alter the protein RNA’s
expression level, or occur in a functional region. [6, 19]. Mutations could occur within
the coding region and directly affect the folded protein structure, or affect the regulation
of a gene by occurring in gene regulatory regions, resulting in silencing or overexpressing
proteins, whether in the wrong tissue or at the wrong time [6, 19]. Regulatory regions
could include enhancers, silencers, transcription start sites, splice donor or acceptor sites,
ribosome binding sites, termination signals, or polymerase binding sites [19]. Abnormal
proteins in cancer can cause uncontrolled growth and cell division or suppress other genes
that would function to fix mutations and stop growth. In cancer cells, proto-oncogenes and
tumor suppressor genes can be mutated, resulting in uncontrolled growth and proliferation
[5, 18]. The mutation landscape is important to understand phenotypic impact because
knowing the genomic location of mutations is crucial to understanding possible phenotypic
changes. Additionally, the clustering of mutations is important because as the number of
mutations increases close to one another, the likelihood of functional impact increases.
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Single nucleotide variants and polymorphisms (SNVs and
SNPs)

Single nucleotide variants (SNVs) or point mutations are the most common genetic variant
occurring throughout the genome. A SNV is a one base pair substitution [1, 20, 21].
Single nucleotide polymorphisms (SNPs) are differences in a single nucleotide between
individuals, where the variant must be present in at least more than 1% of the population
[20]. SNP refers to the frequency in the population or inheritance, whereas SNV does
not [6]. In a diploid organism, genotypes at SNP loci can be homozygous, with the same
nucleotide at the SNP locus between a pair of parental chromosomes, or heterozygous,
with two different nucleotides at the SNP loci. SNPs can occur in any DNA location
[1, 20], and arises through single point mutations, most frequently originating from
errors in replication [2]. When SNPs arise within a gene, they can be neutral or can
affect phenotype and fitness positively or potentially negatively, as in the case of disease.
Additionally, SNPs occurring in regulatory regions of genes can potentially affect gene
expression with different fitness effects [21]. SNPs have been used as markers of genetic
variation to study contributions of such variation to diseases or complex traits [1]. SNPs
contribute to cancer, type II diabetes and other diseases [1, 2].

1.3.3

Copy number variants (CNVs)

Structural variants are large genomic alterations, approximately 1 Kb in size, including
insertions, deletions, inversions, duplications and translocations [22]. Copy number
variants (CNV) are a subtype of structural variants. CNVs are large (500 bp – 1
Mb) segments of DNA found in variable amounts between individuals and populations
[1, 3, 23, 24]. CNVs arise due to deletions or duplications of segments of DNA caused by
errors in DNA replication and recombination, during non-allelic homologous recombination,
fork stalling and template switching, non-homologous end joining due to double-stranded
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breaks, mobile element insertion, and retrotransposition [17, 22, 25, 26]. Polymerases are
prone to stalling at regions that are difficult to replicate, including repeat regions and
areas of high sequence similarity [17, 25]. This occurrence is referred to as replication
stress and can lead to stalled replication forks. The polymerase will switch to another
active replication fork to bypass the area, leading to possible misalignment and CNV
formation [25]. These errors lead to a gain or loss of genetic information, and CNVs
can disrupt gene dosage if they contain a gene [1, 3, 23, 24, 26]. Copy number variable
regions (CNVR) are CNVs occurring at the same genomic location in multiple samples,
either due to shared inheritance or mutation hotspots [26, 27]. CNVs have been found
globally across the genome [27]. Research has shown that CNVs play roles in diseases
including Hemophilia A and Thalassemia [24], and in complex traits including autism,
Alzheimer’s disease, and schizophrenia [3, 24]. Sequence analysis of CNVs showed genes
and regulatory sequences frequently overlapped or encompassed within CNVs, which
confirms CNV’s relevance to phenotypic variation and complex phenotypes [26].

1.3.4

Driver gene mutations

Specific mutations can confer advantageous or deleterious functions within a cell or
organism. Cells will positively select for or favour the acceptance of mutations that
confer a positive advantage, while negatively selecting or favouring the loss of mutations
with deleterious effects to the cell [18]. This selection will lead to a subset of mutant
cells, or clones, that have a selective advantage over cells without the advantageous
mutation. From a health perspective, what phenotypes are advantageous and deleterious
to a normal cell differs from that of a cancer cell. In cancer, driver mutations confer a
growth advantage, leading to tumorigenesis and proliferation. Driver mutations confer
advantageous phenotypes, subject to positive selection and increased fitness [5, 18]. In
contrast, passenger mutations confer less or no apparent growth advantage and thus tend
to have no positive or negative selective advantage. Driver genes confer a crucial growth
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advantage to a cell when mutated, leading to further genomic instability, proliferation,
and tumorigenesis [5, 28]. Methods used to differentiate driver and passenger mutations
include frequency- and function-based methods [28], or analyzing structural changes in
the translated protein associated with mutations under positive selection [5]. Driver
genes can be classified as proto-oncogenes or tumor suppressors, depending on whether
they are activating or inactivating mutations. When mutated, proto-oncogenes are either
activated or activate a downstream gene, providing a growth advantage to the cell. Tumor
suppressors are inactivated, allowing uncontrolled growth and proliferation [28]. Mutations
in proto-oncogenes and tumor suppressor genes produce phenotypes that are advantageous
and positively selected for in cancer cells [18]. Identification of driver genes has been the
focus of many studies, but researchers must be able to classify driver genes and passenger
mutations to understand their complex dynamics in tumorigenic potential [18].

1.4

Genetic variation in mouse models of
human genetic variation and disease

Mus musculus, more commonly referred to as the house mouse or the laboratory mouse,
is an important model organism commonly used in genetic research studying complex
phenotypes and genetic variation. For the past century, human biology and disease
research used mice as a model organism because of their short generation time, large
litter size, and the ability to manipulate their genome easily [29]. For example, different
breeding schemes can control the level of genetic heterogeneity between individual mice
[30]. In 2002, the mouse genome was sequenced, characterized and made available to the
public. The characterization found that 99% of mice genes have a homolog in the human
genome, making them ideal organisms for experiments modelling the human genome [31].
Mouse models can be classified depending on their origin, breeding scheme, and levels
of diversity in the genome. There are seven primary classifications of laboratory mice:
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(1) inbred, (2) wild-caught, (3) wild-derived, (4) outbred, (5) recombinant inbred, (6)
collaborative cross, and (7) diversity outbred mice.
Inbred mice (1) have been frequently used to model the human genome in experiments
because of their genomic stability [32]. Inbred mice are laboratory mice consecutively
brother-sister mated for more than 20 generations, resulting in mice homozygous at
approximately 99% of all loci, with little to no variation between mice [29, 32]. Additionally,
inbred mice are well characterized, and as of 2011, there are genomic sequences of 17 inbred
strains of mice available [30]. Inbred mice are beneficial because little to no variation
in mice minimizes variability in experiments [29]. One disadvantage is that complete
inbreeding in mammals is not common in nature and, therefore, does not represent the
levels of heterozygosity and genetic variation seen in humans well.
Wild-caught mice (2) are live-trapped and transported to a laboratory for research,
whereas wild-derived mice (3) have been bred in the laboratory for multiple generations.
Both wild-caught and wild-derived mice have higher levels of genetic diversity than inbred
mice and together are a diverse group, but wild-derived mice are inbred within the
laboratory [32]. Once in the laboratory, wild-caught and wild-derived mice will become
very similar unless new mice are periodically introduced into the stocks [33]. Both groups
of mice originated in a natural environment and are generally exposed to more antigens
than the average laboratory mouse, making them ideal candidates for immunology studies
[33, 34]. A disadvantage to wild-caught and wild-derived mice is that the genomes of
individual mice are not well defined. Thus, information on the heterozygous landscape
of each mouse is unique and undefined. This undefined landscape creates difficulty
making predictions and reproducing results for confirmation, considering the uniqueness
of individual mice.
Outbred mice (4) are laboratory mice that are bred to be a more genetically diverse
group and to have higher levels of heterozygosity in their genomes. Breeding mice with
different genetic backgrounds leads to recombination events resulting in mosaic genomes
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with regions of heterozygosity and increased diversity. Outbred mice have a distinct
combination of alleles due to unique recombination patterns and have more considerable
variation in SNPs [35, 36]. Compared to inbred mice, outbred mice tend to have more
offspring [35, 37], due to inbreeding depression which leads to a decrease in the ability to
have an abundance of offspring in inbred mice [38, 39]. Inbreeding can lead to an increase
of deleterious recessive alleles within a population or a decrease in favourable heterozygote
combinations [38, 39]. Overall, outbred mice may be better subjects for most biomedical
research due to their higher levels of genome variation, which better represents the human
genome [37].
Recombinant inbred mice (5) are bred from two distinct inbred lines to create progeny
that are a mosaic of the two parental inbred lines. Recombinant inbred mice are commonly
used for genetic mapping [40]. The recombinant inbred collaborative cross strain (6) of
mice are bred from eight diverse inbred mouse strains (C57BL/6J, A/J, NZO/HiLtJ,
129SI/SvImJ, NOD/ShiLtJ, CAST/EiJ, PWK/PJ), including three with wild origins
to increase diversity [41–43]. The parental mice are intercrossed and then inbred over
three generations to establish collaborative cross strains, which leads to greater allelic
diversity and more SNPs [41, 42]. The diversity outbred mice (7) are designed to be
unique mice, thus being the most genetically diverse stock of mice used in research. Mice
from the collaborative cross strains are randomly mated to establish diversity outbred
mice [43, 44]. Both strains display a range of observable phenotypes, have a high degree
of heterozygosity, and unique alleles. Collaborative cross and diversity outbred mice are
commonly used for mapping quantitative trait loci and phenotyping studies [42–44].
In addition to classifying mouse models dependent on their genetic background and
levels of genomic diversity, mouse models can be classified depending on the phenotype
they are used to study, whether proxies for a complex trait or a disease. Despite this
variation in available mouse models, there is not a model that fits all research needs, and
current models may need to be further characterized to suit a research question better.
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Missing genetic variation in mouse models

While previous research has well-characterized SNPs and CNVs in commonly used
classical and inbred mouse models, SNPs and CNVs are currently undetected in many
other mouse models used to study complex phenotypes and diseases. The development
of new technologies has provided the methods to detect variants in these models [22].
Seventeen strains of inbred mice have had SNPs, insertions, deletions, structural variants
and functional variants detected and analyzed in their genomes [30]. Forty-one strains of
inbred mice have a characterized CNV landscape, including detected CNVs affecting genes
related to human disease [45]. While outbred mice contain higher levels of genetic variation
and are used to study complex phenotypes and disease, research has not characterized
them to the same extent as inbred mice. One study assessed 66 strains of commercially
available outbred mice for use in genome-wide association studies [46]. However, it
did not focus on cataloging the genetic variation and genes affected in these strains.
In addition to outbred mice, the landscape of genetic variation in other specific mouse
models of complex phenotypes needs to be characterized to the same extent as inbred mice.
This characterization would improve understanding of complex phenotypes, variation in
phenotype, clinical outcomes, and drug response. Considering the critical role mouse
models play in research, it is crucial to learn about the genetic variation in the mouse
genome.
Missing heritability refers to the knowledge gap of variants and their contributions to
phenotypes [47]. Similar to the missing heritability of complex traits and diseases in the
human genome, there are variants in mouse models that need to be defined to accurately
study and understand complex traits and diseases in mouse models. Determining the
base levels of genetic variation for outbred mouse strains and disease mouse models will
help elucidate the phenomenon of Heterozygote Instability. Methods and approaches to
detect genetic variation in mouse models will be further explained below.
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Methods to characterize missing
genetic variation

It is essential to detect variants and mutations in the genome to elucidate the genetics
of complex phenotypes and diseases. DNA microarrays and next-generation sequencing
techniques are the leading genomic methods used to detect genetic variation and mutations.
While Sanger sequencing and digital droplet PCR are the leading techniques to confirm
previously detected variants. Both detection and confirmation methods will be discussed
below. Multiple factors must be considered to choose the most appropriate genetic
variation detection method. The specific hypothesis or question to be answered must be
analyzed to determine the scope of the project. The best method will differ depending
on whether the project evaluates one gene, multiple genes, the whole genome, or a
specific set of disease-related genes and depends on the information known before this
research. Methods differ depending on whether the research project is looking to discover
new variants or confirm previously detected variants. Finally, there are budgetary
considerations.

1.6.1

Detection of genome-wide genetic variation

DNA microarrays are a method used to detect SNPs and CNVs at a low cost. Microarrays
allow a rapid, simple analytical pipeline to analyze the data that provide high-resolution
analysis of SNP and CNV genetic variation genome-wide. The Mouse Diversity Genotyping
Array (MDGA) is an Affymetrixr microarray used for genotyping mice and assessing
genetic diversity. The MDGA was modelled after the Genome-Wide Human SNP Array
6.0 and designed based on the C57BL/6J mouse strain reference genome [48]. The MDGA
uses 493,290 SNP loci, and 421,905 Invariant Genomic Probe (IGP) loci to detect SNP
and CNV genotype calls within a mouse sample [48, 49]. The MDGA has eight SNP
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probes designed to detect either the reference/major (A) or alternative/minor (B) allele.
A duplicate probe for both the sense and antisense strand creates redundancy and controls
for position effects. Duplicate probes are placed at different locations on the microarray.
IGP probe sets contain six probes per exon — a proximal, medial, and distal probe for
the sense and antisense strand. Calling three consecutive probes increases the accuracy of
CNV calls [48].
Next-generation sequencing (NGS) is a massively parallel sequencing method used
in genomics and transcriptomics. Millions of small fragments of DNA are sequenced
simultaneously so that each DNA nucleotide is sequenced multiple times. This repeat
sequencing increases the read-depth and sensitivity to improve the accurate detection
of variants. The analytical pipelines used are more complex than pipelines used for
microarrays but provide more sequence information and increased genome coverage. NGS
can be used to sequence the entire genome or a selected subset. Applications of NGS
include whole-genome sequencing (WGS), whole-exome sequencing (WES), targeted-exome
sequencing (TES) and RNA-sequencing. WGS detects a species’ entire DNA sequence
and allows the discovery of genetic aberrations, including SNPs, deletions, insertions and
CNVs, in coding and non-coding regions. WES detects all protein-coding genes in the
genome by selecting only the subset of DNA, known as exons, which encodes proteins.
WES detects the sequence of the exons plus 150 nucleotides into the neighbouring introns
and splice junctions. The majority of disease-causing mutations occur in exons, and
thus, WES is an excellent method for detecting and discovering disease-causing variants.
TES detects the sequence of a select number of genes or selected coding regions within
genes of interest. TES can be custom designed or purchased with preselected content.
Disease panels focusing on a select set of genes or gene regions with known associations
with a disease are available. TES is a cost-effective and efficient approach to detect and
confirm driver gene mutations and de novo passenger mutations in a chosen subset of
genes. RNA-sequencing measures the levels of mRNA molecules expressed, known as
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the transcriptome, from the genes of an organism. RNA-sequencing allows analysis of
how expression levels differ in different tissues or with a specific disease or treatment.
Mutations that alter RNA levels can also be detected through RNA-sequencing when both
control and experimental samples are present [50]. WGS provides the highest coverage of
the genome and the most significant potential to detect new variants. However, WES,
RNA-sequencing and TES allow for less expensive, higher depth analysis of regions of
interest and detection of possible disease-causing variants [51]. Two things that drive
the selection of the research approach are the scope of the research question and budget.
TES is the choice for large-scale targeted mutation analysis. WES is the low-cost option
for broad discovery, and RNA-sequencing is comparable to WES in terms of discovery
but limited to the biosample transcriptome. WES gives the best option to study HI in
functionally relevant areas of the genome.

1.6.2

Confirming previously detected genetic variation

Sanger sequencing and digital droplet PCR (ddPCR) are genetic methods used to confirm
previously detected genetic variation and mutations in the genome. Sanger sequencing is
used to validate variants in genes or sections of DNA, including SNPs and small insertions
or deletions. ddPCR is a method used for amplification and quantification of DNA,
commonly used for validation of CNVs.

1.7

Thesis goal and specific objectives

Given that the HI hypothesis formulated from observations in plants has yet to be formally
tested in mammals, and there are similar mutational mechanisms in plants and mammals,
mouse models with high levels of heterozygosity are proposed as ideal models for the
study of HI. Previous evidence implicates HI during meiosis, but it is uncertain whether
HI is only germ-cell specific or if HI occurs in somatic cells as well. Certain mouse
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models provide a discontinuous landscape of high heterozygosity suitable for detecting
potential evidence of mutagenesis associated with HI in germ and somatic cells and
permit exploration of the associated underlying mutational mechanisms. Two mouse
models are selected in this thesis and evaluated for their suitability to study HI. The
first model is the outbred mouse genetic background generated in two outbred mouse
stocks, CD-1 and NMRI, and aims to investigate HI in germ cells. The second model is
a Ptch1+/- mouse model of basal cell carcinoma and aims to investigate HI in rapidly
dividing somatic cells. Both models require characterization of the heterozygous genomic
landscape and a candidate-associated mutation type represented here by copy number
variants. Well-characterized proxies will allow for testing the HI hypothesis, elucidation
of HI-associated mutational mechanisms, and the genetic variation contributing to the
missing heritability in complex phenotypes.
Outbred mice better represent the genetic variation found in the human genome than
inbred mice [35, 37], which are well-defined and characterized [30]. The full extent of
germline genetic variation in outbred mice is presently not characterized - in particular,
the extent and nature of CNVs in the genome are underreported. CNVs are known to
impact gene dosage and affect complex phenotypes, and outbred mice are frequently
used to study these phenotypes [52]. CD-1 mice are used to study genetics, toxicology,
carcinogenesis and aging [53], whereas NMRI mice are used to study general biology,
toxicology and pharmacology [54]. Both stocks are used to study toxicology due to the
high variation between mice, as inter-animal variation is highly valuable in assessing
unique susceptibility and responses. Thus, to use CD-1 and NMRI outbred mice as a
valid proxy, these CNVs need to be catalogued. Additionally, the genomes of outbred
mice provide a unique opportunity to examine HI, as known breeding schemes suggest
the genomes of CD-1 and NMRI mice consist of clusters of high heterozygosity separated
by clusters of homozygosity. This discontinuous landscape is ideal for examining HI.
Characterizing the CNV landscape of outbred mice and the heterozygosity throughout
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their genomes will allow further elucidation of this phenomenon.
Human BCC tumors are well-known models of very high levels of acquired genetic
variation and provide an excellent candidate to study the phenomenon of HI in rapidly
dividing cells. With UVB exposure, mouse models of BCC develop tumors that accurately
represent human tumors [55]. BCC mouse models provide a controlled environment to
track somatic mutations and analyze whether HI occurs during replication in rapidly
dividing cells. Additionally, BCC presents a unique opportunity to analyze the conundrum
of benign cancer with very high levels of mutation, strong cancer driver mutations and rich
somatic mutagenesis [56]. This conundrum indicates that the potential of a high mutation
burden in cancers needs to be further studied to understand the complex phenotype of
cancer initiation, malignancy and metastasis. Similar to the characterization of genetic
variation in outbred mice, in order for mouse models of BCC to be good proxies for human
BCC and be effective models to study the HI hypothesis and contributions to complex
phenotypes, the somatic mutations must be detected and characterized within the mouse
model.
Thus, the overall goal of this thesis is to evaluate two mouse models of high genetic
variation for suitability to test the HI hypothesis. The specific objectives and the rationale
for these objectives are as follows:
Objective 1: In Chapter 2, I aim to evaluate the genetic diversity in two stocks of
outbred mice, CD-1 and NMRI, as proxies for human genetic diversity and suitability
for the study of HI. Additionally, I aim to examine the spatial association of CNVs to
localized regions of heterozygosity.
Aim 1: To detect the chromosomal heterozygous landscape at SNP loci in two outbred
mouse stocks, CD-1 and NMRI.
The mouse diversity genotyping array (MDGA) detects SNPs at 493,290 SNP loci,
and statistical analysis pipelines are used to portray the distribution of heterozygous SNP
loci. The predicted discontinuous landscapes of heterozygosity differ between outbred
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mouse stocks, given their different breeding histories.
Aim 2: To detect and characterize the CNV landscape in two outbred mouse stocks,
CD-1 and NMRI.
The MDGA detects genome-wide CNVs using 493,290 SNP loci and 421,905 invariant
genome probes. Considering the higher level of genetic variation and heterozygosity
in outbred mice, it is predicted that there will be multiple CNVs detected per mouse,
with features of CNVs, including length, copy number state, genic impact and location,
differing between the two outbred mouse stocks. Genic impact involves pathway and gene
ontology analysis.
Aim 3: To compare the level and nature of genetic variation in outbred stocks to reported
levels of heterozygosity and CNVs in inbred mice, wild-caught mice, and wild-derived
mice.
The CNV landscape and profile of CNVs detected in Aim 2 are compared between
CD-1 and NMRI mice and reported CNV profiles of inbred, wild-caught and wild-derived
mice. It is predicted that the two outbred mouse stocks have higher heterozygosity levels
and CNVs than inbred mice but less than wild-caught and wild-derived mice.
Aim 4: To assess the spatial association between heterozygosity at SNP loci and CNVs
as indirect evidence consistent with the Heterozygote Instability hypothesis.
Using the characterized landscapes from Aim 1 and Aim 2, spatial statistical tools
are used to analyze the landscape of heterozygosity and the landscape of CNVs per
chromosome to detect possible proximal association of CNVs to clusters of heterozygosity.
According to the tenets of the HI hypothesis, CNVs are predicted to be more numerous
with higher levels of heterozygosity and proximal to greater density of heterozygosity.
Objective 2: In Chapter 3, I aim to evaluate mouse models of BCC as proxies for human
genetic diversity and suitability for the study of HI with consideration of heterozygosity
and somatic mutations arising in the context of tumorigenesis.
Aim 1: To complete a systematic literature review of BCC genic mutations to evaluate
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the reported genetic variation in human BCC and in mouse models of BCC.
A systematic literature review between the years 1990 and 2020 was performed, and
two lists of reported mutations were compiled, one for human BCC and one for mouse
models of BCC.
Aim 2: To define the knowledge gap between the reported mutations in human BCC
tumors and reported mutations in mouse models of BCC.
The lists of mutations compiled from Aim 2 were compared between human and mouse
BCC. It is expected that human and mouse BCC share similarities.
Aim 3: To design an experimental workflow to detect genetic variation in mouse models
of BCC to characterize this model for the study of Heterozygote Instability.
Considering the extent of the knowledge gap between humans and mice identified in
Aim 2, multiple experimental designs are presented to characterize the mutation burden
in BCC mouse models at different resolutions and sensitivities.
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Chapter 2.
Characterization of genetic variants
in discontinuous landscapes of
heterozygosity in two outbred
mouse stocks
2.1

Introduction

Genetic variants contribute to differences between individuals and variations in complex
phenotypes, health, and clinical outcomes. However, the full extent of genetic contributions
to many complex phenotypes, phenotypic diversity, aberrant or atypical phenotypes and
fitness are not entirely understood. This gap in knowledge regarding how the genetic
variants and their contributions can affect phenotypes is referred to as missing heritability
[1] and filling this gap is a focus of research. To better understand how genetic variants
affect complex phenotypes, mutational mechanisms associated with genetic variation must
also be defined. The mutation rate is not constant along the chromosomal sequence,
and while multiple mechanisms are known, all mechanisms underlying this are not fully
understood [2]. Variation in mutation rate can be sequence-dependent. For example,
in humans and mice, higher rates of C to T substitutions are seen more frequently at
CpG sites or CG dinucleotides [3–5]. Additionally, repetitive sequences or sequences with
high similarity can cause polymerase slippage or misalignment during DNA replication
or DNA repair [5]. Elucidating the mutagens and mechanisms of mutations will create
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opportunities for better understanding sources and the impact of genetic variation in
complex phenotypes.
Yang et al (2015) was the first to demonstrate a connection between heterozygosity
and mutation rate through investigating SNP heterozygosity and small insertions and
deletions in Arabidopsis [6]. During meiosis, plants with high levels of heterozygosity have
higher mutation rates than plants with lower levels, and the mutations were occurring
in close proximity to heterozygous loci and crossover events [6]. The phenomenon of
increased heterozygosity connected to increased mutations was then tested in peach plants
by crossing either intra-species plants or inter-species plants. Xie et al (2016) found
that hybrid plants had higher mutation rates, comparable to results demonstrated in
Arabidopsis [7]. The specific phenomenon observed in Arabidopsis and peach has not
yet been reported in mammals. HI has been computationally demonstrated with local
heterozygosity and microsatellites in 1163 human genome sequences from the 1000 Genome
Project [8]. Similar genetic variants and mutational mechanisms exist in Arabidopsis and
mammals, including point mutations, small insertions and deletions and CNVs [9–12],
and an increased level of mutations at repetitive DNA sequence and near transposable
elements [12], and UV-induced mutagenesis [10]. This likeness indicates that similar
mutational mechanisms, like HI, may occur in mammals where they are poorly studied.
HI could be measured by identifying heterozygosity at single nucleotide polymorphisms
(SNPs) across the genome as they are easily assayed using microarrays.
While there are many types of genetic variants, this study uses SNP genotypes to
measure heterozygosity and copy number variants (CNV) to measure mutation occurrence.
The goal is to characterize heterozygous SNP and CNV landscapes in a constitutive
genome and look at their spatial associations. SNP heterozygosity can have discontinuous
landscapes with localized variation that ranges from very high to very low levels in different organisms of the same species, which provides an ideal landscape to investigate HI.
Research implicates SNPs and CNVs in disease and complex phenotypes, thus characteri-
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zation is important [13–17]. CNVs are good candidates for the study of HI induction given
their mechanistic association with replication and recombination, known genic impact and
impact on complex phenotypes [14, 18, 19]. CNVs occur most frequently due to DNA replication and recombination errors caused by chromosome misalignment, polymerase stalling,
or replication stress [14, 18, 19]. CNV formation may occur during non-allelic homologous
recombination, fork stalling and template switching, non-homologous end joining due to
double-stranded DNA breaks, mobile element insertion, and retrotransposition [14, 18, 19].
A potentially underappreciated mutational mechanism is how heterozygosity acts to
increase mutations locally or proximally during DNA replication and recombination.
To fully characterize the CNV landscape in a model, the nature of CNVs must be
defined, including location, length, copy number state, recurrence, genes affected, and
copy number variable regions (CNVR) – a region of the genome that a CNV overlaps in
multiple individuals [17, 20]. Researchers examined CNVRs in humans and found that
CNVRs encompassed more of the genome than SNPs, but previously have not been a
focus of characterization studies [17]. This finding indicates that CNVs should be defined
in each model of interest to study and understand associated mutational mechanisms and
contributions to phenotypic variation and complex traits.
Mutation research often uses inbred mice as models, but their genetic background
precludes analysis of the impact of heterozygosity. Outbred mice provide the opportunity
to examine mutagenesis in a genome landscape of high heterozygosity, with distinct
regions of high heterozygosity and regions of high homozygosity, creating discontinuous
segments of heterozygosity along the genome. The discontinuity of heterozygosity in the
genomes of these mice contains regions of dense clustering of heterozygosity separated
by desert regions with low or no heterozygosity, resulting from how outbred mice are
bred. A discontinuous landscape of heterozygosity is ideal for examining whether or not
heterozygosity is contributing to mutagenesis. This landscape allows first the assessment
of CNVs and a possible association with heterozygosity, followed by examining the nature
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and distribution of the SNP heterozygosity to infer mutational mechanisms associated with
deletion or duplication creating CNVs. In comparison, wild-derived and wild-caught mice
have higher levels of genetic diversity than inbred mice and are a diverse group [21], with
the expectation being that the heterozygous landscape of wild-derived and wild-caught
mice are uncharacterized and more random compared to the genomes of outbred mice.
Similarly, the recombinant inbred collaborative cross strain of mice has higher levels of
genetic variation due to originating from eight diverse inbred mouse strains, three with
wild origins [22–24]. Finally, diversity outbred mice are bred to be the most genetically
diverse group of mice through randomly mating mice from the collaborative cross stock
[24, 25]. Both collaborative cross and diversity outbred mice display a range of observable
phenotypes, have a high degree of heterozygosity, and unique alleles [22–25]. The increase
of genetic variation seen in the wild-derived, wild-caught, collaborative cross, and diversity
outbred strains creates a challenge for predicting the heterozygous genomic landscapes
and reproducing genomic locations where HI can be studied. The discontinuous landscape
of heterozygosity presented in the genomes of outbred mice is ideal for investigating
the mechanistic potential of heterozygosity increasing CNV formation due to a more
controlled and predictable environment for hypothesis testing. It is this clustering and
spacing of heterozygosity that this chapter will aim to characterize and examine with
respect to localized effects on CNV occurrence.
Two commercially available stocks of outbred mice, CD-1 (Caesarian Derived-1) and
NMRI (Naval Medical Research Institute) [26] present a unique opportunity to examine
mutagenesis in two distinct landscapes of clustered heterozygosity. Not only is there
variation in the clusters of heterozygosity between CD-1 and NMRI mice, but there is
variation in clustering between individual mice within the two stocks. More specifically,
there are differences in genetic variation within a mouse between chromosomes and
different regions of chromosomes. Thus, CD-1 and NMRI mice are ideal models to
study if local heterozygosity affects mutations. Both stocks originated from a group of
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200 wild-caught mice with higher levels of heterozygosity in their genome (Figure 2.1).
Researchers transported nine mice from Switzerland to the USA, where the mice were
inbred. The CD-1 stock was inbred for approximately 15 generations, whereas the NMRI
stock was inbred for approximately 51 generations. This inbreeding introduced clusters
of homozygosity to the genomes of both stocks of mice. The clusters of heterozygosity
are discontinuous throughout the genome, separated by desert regions with low to no
heterozygosity. Both CD-1 and NMRI mice were confirmed to have higher levels of
variation than inbred mice [27, 28]. Finally, researchers maintain both stocks through
outbreeding, which re-introduced heterozygosity and increased genetic variation [26]. This
breeding history leads to genomic heterozygosity patterns that make CD-1 and NMRI
mice ideal models for testing the spatial distribution of heterozygosity and mutations.
Given that they have different levels and spatial distributions of heterozygous loci, their
genomes provide unique conditions to see if mutations occur in localized regions of
clustered heterozygosity or clustered homozygosity. The variation within the genomes of
CD-1 and NMRI mice creates unique genomic contexts that allow for in-depth and varied
analysis and comparison of heterozygosity and CNV occurrence between mice, between
chromosomes and within chromosomes.
Pasteur Institute, Paris
- Colony started with
200 wild-caught
mice supplied by an
unknown dealer

1920
Strasburg
- Coulon
obtained mice
from Pasteur
Institute

1924
Lausanne
- Coulon moved to
Lausanne with
mice from
Strasburg

Types of breeding:
Brother-sister mating – mate siblings to maintain
homozygosity and stability
Random breeding – randomly select breeding
partners for mice (not siblings)
Inbreeding – commonly brother-sister mated
Outbreeding – breeding mice from different
lineages to increase genetic variability

1926
Rockefeller Institute, USA
- Lynch obtained 2M and
7F mice from Coulon
- Brother-sister mated
mice for her cancer
research

1937
National Health Institute
- Poiley inbred mice as
NIH/PI for 51
generations

1955
Naval Medical Research
Institute
- Founded NMRI
- Random bred
- Now, outbred

1928-30
Rockefeller Institute, USA
- Flexner obtained mice
from Lynch at brothersister matings ~3rd to 7th
generation
- Then passed to Carrel
who random bred the
mice

1928-30
Rockefeller Institute, USA
- Leslie Webster obtained
mice from Carrel
- Mice were brother-sister
mated for ~10-12
generations
- Then random bred
1947-48
Institute for Cancer
Research
- Mice were random bred
with selection for high
growth rate and high
productivity (Ha/ICR)
1959
Charles River Breeding
Lab
- Outbred Ha/ICR mice
- Founded CD-1

Figure 2.1: Breeding history of CD-1 and NMRI mouse stocks. Types of breeding
are highlighted in red text and defined in the inset red box.
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Both CD-1 and NMRI mouse stocks have germline genetic variation that has yet to be
characterized and must be defined before the novel complex phenotype of HI demonstrated
in Arabidopsis and peach plants can be evaluated in the genomes of CD-1 and NMRI mice.
CD-1 mice have had a small proportion of heterozygosity and CNVs detected in their
genome, whereas NMRI mice have had neither characterized. The level of heterozygosity
in CD-1 mice was assessed at 3,572 SNPs across the genome to determine the potential of
CD-1 mice as models for genetic studies. However, it has not been assessed on a larger
scale or with greater resolution [29]. CD-1 mice are found to have genetic variation similar
to what is seen in a human founder population, which is a population that originated from
a very small number of individuals [29]. Anxiety-associated CNVs have been analyzed
and catalogued in CD-1 mice [30]. CNVs have yet to be examined in NMRI mice. CD-1
and NMRI mice are the ideal mouse stocks to study the complex phenotype of HI and
begin to fill the knowledge gap surrounding genetic variation and complex phenotypes, in
particular through characterizing the CNV and heterozygous SNP landscape.
This chapter will analyze publicly available genotype array data to detect and catalogue
heterozygous SNP genotypes and CNVs related to complex phenotypes and examine the
spatial distribution of CNVs within the unique background of outbred mice to determine
if heterozygosity is associated with CNV occurrence (Figure 2.2). Combined detection
and characterization of heterozygous SNP genotype and CNV calls was achieved using
the Mouse Diversity Genotyping Array (MDGA) [20, 31]. This array has been used for
genotyping both mouse stocks, and the data are publicly available. Analysis of CNV
calls was achieved using HD-CNV (Hotspot Detector for Copy Number Variants) [32].
HD-CNV examines CNV calls and detects overlapping regions of DNA to identify CNVs
occurring in multiple samples, termed recurrent CNVs or CNVs that occur in one sample
only, termed unique CNVs (Figure 2.3) [32]. This combination of technologies is ideal
for simultaneous SNP and CNV analysis considering sufficient genomic resolution, cost,
efficiency, rapid bioinformatics and publicly available data sets of sufficient sample size.
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404 CEL files were downloaded from the
Center for Genome Dynamics –
101 CD-1 files and 303 NMRI files.
99 CD-1 files and 279 NMRI files passed quality controls

AA
AB
Tissue/DNA extraction,
isolation, and preparation

Mouse Diversity
Genotyping Array

BB
Fluorescence
detection

493,290 SNP loci probes
&
421,905 Invariant Genome
Probes (IGP)

Loss (CN 0 and1)
Gain (CN 3+)

SNP genotyping

CNV calling

Affymetrix Genotyping
Console

PennCNV

Data analysis
•
•
•

Detection and characterization of unique and shared CNVs
Detection of autosomal heterozygous SNP genotypes
Analysis of spatial association between CNVs and
heterozygous SNPs

Figure 2.2: Methods workflow from sample extraction to data analysis. Steps
completed by the Jackson Laboratory are shown by grey arrows and steps completed
in-house are shown by purple arrows. Mouse and laptop images retrieved from SMART
Servier Medical Art.
The spatial distributions of heterozygous SNP loci and CNVs were analyzed using
three plots — rainfall plots, rainbow plots, and J statistic plots [33, 34]. Rainfall plots
portray the genomic landscape of heterozygous SNP loci across the genome, allowing
the visualization of clusters, defined as heterozygous SNP dense regions, and deserts,
defined as heterozygous SNP sparse regions (Figure 2.4). Rainbow plots portray spatial
associations between heterozygous SNP loci and CNVs (Figure 2.5). J function statistically
analyzes the association between heterozygous SNP loci and CNVs, determining possible
relationships and significance (Figure 2.6).
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Figure 2.3: Hotspot Detector for Copy Number Variants (HD-CNV) creates a
heatmap karyotype of recurrent and unique CNVs. A. CNV calls from individual
mice are compiled per chromosome and analyzed for sequence overlap. A CNV that
shares no sequence overlap is unique. Recurrent CNVs share a 40% or greater sequence
overlap. A heat map displays unique and recurrent CNVs, where red represents a higher
number of overlaps, while blue represents a unique CNV. Nodes represent one CNV event,
and edges connect nodes if the two CNV events share sequence overlap. Mouse image
retrieved from SMART Servier Medical Art. B. A traditional human karyotype. Image
retrieved from SMART Servier Medical Art. C. A heatmap karyotype of recurrent and
unique CNVs. The size of each circle is relative to the number of CNV events on that
chromosome. The Y chromosome was not analyzed due to a lack of probe representation.

Chapter 2. Characterization of two stocks of outbred mice

33

Figure 2.4: Rainfall plots portray the landscape of heterozygosity at SNP loci.
Heterozygous SNPs are plotted at their respective genomic location (X-axis) against the
distance (Y-axis) between the heterozygous SNP and its nearest previous heterozygous
SNP locus neighbour plotted on a logarithmic scale. A. If two heterozygous SNPs are
farther apart, the point is plotted higher up versus if two heterozygous SNPs are closer
together, the point falls lower down on the graph. B. Rainfall plots show regions without
heterozygous SNPs, termed deserts, versus regions dense with heterozygous SNPs, termed
clusters, across the chromosome.

Figure 2.5: Rainbow plots display the potential spatial association between
heterozygous SNPs and CNVs. A. CNVs are plotted at their respective genomic
location as red dots along the X-axis. Heterozygous SNPs are plotted at their genomic
location as black dots against their distance to the closest CNV. If the heterozygous
SNP is close to a CNV, the particular point is plotted lower on the Y-axis, indicating a
possible spatial association. B. A rainbow plot of a chromosome with a potential spatial
association between two CNVs and heterozygous SNPs.
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Figure 2.6: J function is a statistical tool used to analyze the spatial distribution of heterozygous SNPs relative to CNVs. A. Four possible distributions
of heterozygous SNPs relative to a CNV: distal — CNV occurs far from heterozygous
SNPs, no association, proximal — CNV occurs close to heterozygous SNPs, or both —
CNV occurs first close to or far from heterozygous SNPs, and then the chromosomal
heterozygous landscape varies between regional clusters of heterozygosity and clusters of
homozygosity. B. J statistic assesses the significance of the association after running 1000
simulations and produces two confidence bands. C. If the observed J function crosses the
confidence bands, the association is significant, either the upper confidence band (distal),
the lower confidence band (proximal), or crosses one confidence band and then the other
(both). If the function does not cross the confidence bands, there is no association between
the heterozygous SNPs and CNVs on that particular chromosome.

2.1.1

Research goal, central hypothesis, and specific objectives

Research goal: The purpose of this study is 1) to detect and characterize SNP and CNV
genetic variation in CD-1 and NMRI mice to fill missing heritability potentially related to
complex phenotypes, 2) to confirm the discontinuous landscape of heterozygosity at SNP
loci, and 3) to analyze the spatial association between CNVs and heterozygous SNP loci
to test the Heterozygote Instability hypothesis with germline mutations in outbred mice.
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Predictions: CD-1 and NMRI mice will display differences in the content and nature
of CNVs compared to each other and inbred mice. Both stocks will show discontinuous
heterozygosity at SNP loci, with NMRI mice having less heterozygosity and greater deserts
than CD-1 mice. Given the recent observation in Arabidopsis and peach plants that there
is a connection between heterozygosity and mutation rate, the proximal occurrence of
insertions and deletions, and the similar DNA sequence mutational mechanisms in plants
and mammals, both stocks will have CNVs close to localized regions of heterozygous
SNP loci across the genome. These mouse models provide an opportunity to gauge the
association of CNV occurrence with higher levels of chromosomal SNP heterozygosity.
Due to the increased levels of clustered heterozygosity in CD-1 mice, there will be an
increased number of CNVs per mouse in CD-1 mice compared to NMRI mice.

The specific objectives are:
1. To detect the chromosomal heterozygous landscape at SNP loci within CD-1 and
NMRI mice.
2. To detect and characterize the CNV landscape and identify CNVRs shared within
and between CD-1 and NMRI mice.
3. To compare the level and nature of genetic variation in CD-1 and NMRI mice to
reported variants in inbred mice, wild-caught mice, and wild-derived mice.
4. To explore HI through examining the spatial association of CNVs and heterozygous
SNP loci across the genome.
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Materials and methods
Samples and SNP genotype and CNV calling

A total of 404 publicly available CEL files were downloaded – 101 CD-1 and 303 NMRI
mouse files, from the Center for Genome Dynamics at the Jackson Laboratory [35]. Two
CD-1 and 15 NMRI files were excluded due to not meeting a 97% SNP genotype call
rate or issues downloading the files. Accordingly, this study examined the autosomes
of 99 CD-1 (43 males and 56 females) and 279 NMRI (all males) mouse CEL files and
the X chromosome of all-male mice (Appendix 2A). A list of filtered SNP probes was
generated by previous Hill laboratory members and used for SNP genotyping in this
chapter [20, 36, 37]. Probes on the Y chromosome represented too few sites, thus there
was an insufficient amount of data for analysis. Generally, SNP genotype and CNV calling
and analysis follow a previously reported pipeline [20] and are discussed in more detail
below.
To detect the heteozygous landscape at SNP loci, SNP genotype calls were generated
using Affymetrix Power Tools [38], which uses the BRLMM-P algorithm (Bayesian
Robust Linear Model with Mahalanobis distance classifier - Perfect-match probes) [39].
The algorithm clusters calls into three categories, AA (homozygous, major allele), AB
(heterozygous) and BB (homozygous, minor allele). Any calls that do not fall within those
categories are categorized as a ‘no call.’ To detect and characterize the CNV landscape,
CNVs were identified using PennCNV, which applies an HMM algorithm (Hidden Markov
Model) to the genotype clustering file produced in the Genotyping Console [20] to produce
a Log R Ratio (LRR) and a B allele frequency (BAF) file. Using these files, an in-house
script and the reference genome (UCSC:mm9), PennCNV detects the copy number (CN)
state – complete loss (state 0), partial loss (state 1) or gain (state 3 and 4) [40]. A
separate run was performed to detect the CNVs on the X chromosome by applying the
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-chrX option [40]. CNV calls were filtered to contain at least three probe markers with
the same intensity, length between 500 bp to 1 Mb, and LRR less than 0.35, and a BAF
drift less than 0.01. The detected SNPs and CNVs were used in subsequent methods to
characterize the landscape of heterozygous SNPs and CNVs in both CD-1 and NMRI
mice.

2.2.2

Genetic distance determination and phylogenetic analyses

To compare the level of genetic diversity in CD-1 and NMRI mice to each other and to
human genetic diversity, SNP genetic distance was calculated by totalling the number
of loci between pairs of samples that did not share the same genotype call (AA, AB,
BB) divided by the total number of SNP loci (Appendix 2B). CNV genetic distance was
calculated by totalling the number of CNV genotype differences (CNV loci that differ in
copy number (CN) state: 0, 1, 2, or 3+) between pairs of samples divided by the total
number of SNP and invariant genomic probe (IGP) loci. A pairwise distance matrix was
created [20]. Neighbour-joining trees were created for CD-1 and NMRI mice using the
SNP and CNV genetic distance matrices by applying the Ape (Analyses of Phylogenetic
and evolution) package on Studio R version 3.4.1. These trees were saved as Newick
files and uploaded to FigTree for creating and colouring the Neighbour-joining trees. A
select set of samples identified to be closely related through genetic distance analysis were
coloured in both the SNP and CNV phylogenetic trees to visualize how related samples
are placed throughout each tree. A Mantel test was performed to test the association
between the SNP genetic distances and CNV genetic distances, using a P-value cut off
less than 0.05.

2.2.3

Analysis of the landscape of heterozygosity at SNP loci

To detect the clustering and landscape of heterozygosity at SNP loci, spatial statistical
tools were used to visualize the autosomal genomic landscape of heterozygous SNP
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genotypes [33, 34]. Rainfall plots [41] were adapted to plot the inter-locus distance
between heterozygous SNP genotypes. Rainfall plots provide a visual representation
of regional density in heterozygous SNP genotypes per chromosome, including clusters
and deserts. The detected chromosomal landscape of heterozygous SNP loci was then
compared to the detected CNV landscape, discussed further below.

2.2.4

Detection of recurrent CNV regions and unique CNVs

Recurrent CNVs are deletions and duplications observed in more than one mouse at the
same genomic location. To characterize the CNV landscape in terms of CNVRs, recurrent
and unique CNVs were identified using HD-CNV (Hotspot Detector for Copy Number
Variants), using 40% reciprocal overlap [32]. CNVRs are identified using HD-CNV.
Graph files produced by HD-CNV were input into Gephi, an open source for visualizing
networks [42] and formatted using the Fruchterman-Reingold layout. The output images
were normalized for size based on the maximum and minimum number of CNVs for
all chromosomes and then assembled into a heatmap karyotype. A script (Appendix
2C) was written and used to create CNV Landscape Plots (CNV-LP), which portray
the genomic footprint of all CNVs within the genome, showing CNV features including
genomic location per chromosome and CN state. A CNV-LP allows visualization of the
distribution of recurrent and unique CNVs across the genome and allows the identification
of CNVRs or hotspots. Finally, a CNV-LP allows comparisons of CNV landscapes between
mice within a stock and between stocks.

2.2.5

Pathway and GO term characterization of genes overlapped or encompassed by recurrent and unique CNVs

To characterize the CNV landscape in terms of genic content and enriched pathways
and Gene Ontology (GO) terms, an annotated M. musculus genome (GRCm38.p5) was
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downloaded from Ensembl Genome Browser [43, 44]. This annotation file and two files
containing all CNV events in CD-1 and NMRI mice were uploaded to Galaxy – an opensource platform for analyzing biomedical data [45]. Intersect intervals under BEDTools
were used to determine which CNVs contained or overlapped a gene from the annotated
mouse genome [46]. Gene lists were created for all the genes identified separated by CN
state. These lists were individually uploaded into Metascape for enrichment analysis
[47]. GO Enrichment Analysis was performed using The Gene Ontology Resource [48, 49].
DAVID v6.8 (Database for Annotation, Visualization and Integrated Discovery) was used
to find enriched KEGG pathways [50, 51]. Finally, PANTHER (Protein Analysis Through
Evolutionary Relationships) 13.1 was used for gene analysis and pathway enrichment [52].
Enriched terms were included using a P-value cut-off of less than 0.05 and were compared
to identify similarities and differences within and between stocks.

2.2.6

Analysis of spatial association between heterozygous SNP
genotypes and CNVs

To investigate for indirect evidence supporting HI in the genomes of CD-1 and NMRI
mice, spatial statistical tools were used to analyze the distribution of heterozygous SNP
genotypes and CNVs. Possible distributions of CNVs include proximal, distal, varied
(both) or with no association to heterozygous SNP genotypes [33, 34]. Rainbow plots
visualize possible spatial associations between heterozygous SNP genotypes and CNVs. J
statistic is used to determine the distribution and assess the significance of the spatial
association.

2.2.7

Statistical Analysis

To statistically test detected indirect evidence supporting HI, a MANOVA test was
performed to analyze the potential significance of the association between chromosomal
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heterozygosity and CNVs with proximally associated heterozygous SNP loci. A Student’s
t-test was performed to analyze if the potential association was significantly different in
CD-1 and NMRI mice. A Spearman’s rank correlation coefficient analysis was performed to
analyze the correlation between autosomal heterozygosity and the occurrence of proximal
association per autosome.

2.3

Results

2.3.1

Levels of genomic and chromosomal heterozygosity at SNP
loci differ in CD-1 and NMRI mice

To characterize the level of heterozygosity and the heterozygous landscape in CD-1
and NMRI mice, SNP genotyping calls were reported for 493,290 SNP loci. Measures
of diversity for each stock were recorded (Table 2.1). The average heterozygosity per
chromosome was recorded (Table 2.2), and when chromosomes were analyzed individually,
the range of heterozygosity was 7.82-14.20% and 3.03-11.02% in CD-1 and NMRI mice.
CD-1 mice compared to NMRI mice have a higher level of genomic heterozygosity per
mouse and a higher percent heterozygosity on each autosome. These results will be
subsequently used to identify clusters of heterozygosity throughout the genomes of CD-1
and NMRI mice.
Table 2.1: SNP genotyping results by outbred mouse stock.

a

Stock

Samples

CD-1
NMRI

99
279

Call
(%)a
99.75
99.76

No Call
(%)b
0.25
0.24

Heterozygosity
(%)c
10.68
6.20

BB
(%)d
14.70
16.67

BAF
(%)e
40.08
39.54

Percent of calls that were successfully assigned (AA, AB, BB)
Percent of calls not made (neither A nor B)
c
Percent of calls that are heterozygous (major allele and minor allele)
d
Homozygosity of the minor allele
e
B Allele Frequency (BAF): Abundance of the minor allele
b
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Table 2.2: Average heterozygosity at SNP loci per autosome.
Chr
CD-1
NMRI
Chr
CD-1
NMRI

2.3.2

1
10.90
7.49
11
12.73
11.02

2
12.86
9.83
12
10.97
5.57

3
10.41
5.85
13
13.39
6.00

4
5
6
8.89 12.31 10.70
5.13 7.70 4.34
14
15
16
13.43 12.06 7.82
9.16 8.09 4.11

7
10.06
6.72
17
14.20
5.95

8
8.87
4.07
18
10.90
5.77

9
10
9.87 7.84
6.22 3.03
19
11.36
8.49

CD-1 and NMRI mice have similar SNP and CNV
genetic distance values and display relatedness similarly
on Neighbour-Joining trees

To compare the level of genetic diversity in CD-1 and NMRI mice to each other and
inbred, wild-caught, and wild-derived mice, pairwise comparisons between samples were
calculated, and found SNP distance values range from 0.0093–0.18 and 0.0085–0.11 for
CD-1 and NMRI mice. Pairwise comparisons between samples found CNV distance
values range from 0.00011–0.0076 and 0.0002–0.0099 for CD-1 and NMRI mice. The
SNP and CNV genetic distances calculated were used to make Neighbour-Joining trees
for CD-1 (Figure 2.7) and NMRI mice (Figures 2.8). Additionally, the subset of closely
related samples – coloured in purple or blue, respectively, cluster in the SNP trees and
are dispersed throughout the CNV trees (Figure 2.7 and 2.8). A Mantel test determined
no significant difference between the SNP and CNV genetic distances, producing P-values
of 0.08 and 0.73 for CD-1 and NMRI mice.
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Figure 2.7: Unscaled Neighbour-Joining tree for SNP (A) and CNV (B) diversity in the CD-1 stock (n = 99).
Pairwise comparisons were used to create a genetic distance matrix using SNP and CNV genotype calls. Scale bars represent
genetic distance or difference between samples. A subset of closely related samples was coloured (purple) in both trees to visualize
how closely related samples cluster on SNP compared to CNV trees.
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Figure 2.8: Unscaled Neighbour-Joining tree for SNP (A) and CNV (B) diversity in the NMRI stock (n = 279).
Pairwise comparisons were used to create a genetic distance matrix using SNP and CNV genotype calls. Scale bars represent
genetic distance or difference between samples. A subset of closely related samples was coloured (blue) in both trees to visualize
how closely related samples cluster on SNP compared to CNV trees.
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CD-1 mice have a higher average of CNVs per mouse
than NMRI mice, with more gains and longer CNVs yet
a smaller percentage of CNVs that contain or share an
overlapping region with a gene

To characterize the CNV landscape in CD-1 and NMRI mice, CNVs were detected in both
stocks of mice. CD-1 mice had 1690 autosomal CNVs, with an average of 17 CNV calls
per mouse, a minimum of 11 and a maximum of 90 CNVs (Appendix 2D). Comparatively,
NMRI mice had 3935 autosomal CNVs, with an average of 14 CNV calls per mouse, a
minimum of four CNVs and a maximum of 78 CNVs (Appendix 2E). There was a total of
96 and 378 CNVs in male CD-1 and NMRI mice on the X chromosome, respectively. CNV
calls were analyzed on the autosomes of both outbred stocks, compared to the autosomes
of classical, wild-derived and wild-caught mice [20] (Table 2.3) and the X chromosome of
the male mice in both outbred stocks (Appendix 2F). NMRI mice have a much higher
loss-gain ratio than CD-1 mice, indicating a much greater proportion of CN complete and
partial losses. A positive correlation between the number of CNVs per autosome and
increasing autosome heterozygosity was seen in both stocks (Figure 2.9).
Table 2.3: Autosomal CNV calls by mouse stock and copy number state.
Stock
CD-1
NMRI
C57BL/6Jc
WDc,d
WCc,e

Samples
99
279
8
52
19

CNV Calls
1690
3935
90
2611
969

(17.01)
(14.11)
(11.52)
(50.21)
(51.00)

Copy Number Statea
Loss/
0
1
3+
Gainb
65
(0.65) 617 (6.25) 1008 (10.18) 0.68
285 (1.02) 3205 (11.49) 445 (1.59) 7.84
0
(0.00)
38
(4.75)
52
(6.50) 0.73
1214 (23.34) 594 (11.42) 803 (15.44) 2.25
231 (12.15) 491 (25.84) 247 (13.00) 2.92

Values in brackets are normalized by sample count.
Copy number states: full deletion (CN 0), partial deletion (CN 1), and gain (CN 3+)
b
Total number of losses (CN 0 and 1) divided by number of gains (CN 3+)
c
Data retrieved from Locke et al., 2015
d
Wild derived (WD) mice
e
Wild caught (WC) mice
a
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Figure 2.9: Distribution of the average number of CNVs on autosomal chromosomes and chromosomal heterozygosity at SNP loci. Distribution of the average
number of CNVs on the autosomal chromosomes of CD-1 mice (n = 99) are shown
in purple and for NMRI mice (n = 279) in grey. Linear trendlines (dotted lines) are
included for CD-1 and NMRI data and indicate a positive correlation between increasing
chromosomal heterozygosity and average number of CNVs per chromosome in CD-1 and
NMRI mice.
For the autosomes, the average length of CNVs was 93,643 base pairs and 70,583
base pairs in CD-1 mice and NMRI mice. The median length was 54,193 base pairs and
47,858 base pairs in CD-1 mice and NMRI mice. The average length of CNV gains was
122,793 and 146,575 base pairs, and the average length of CNV losses was 50,559 and
60,893 base pairs for CD-1 and NMRI mice, respectively (Figure 2.10). CN gains in CD-1
mice display a bimodal distribution of lengths, with a large group of smaller CNVs and a
smaller group of longer CNVs.
CD-1 mice have more CN gains, whereas NMRI mice have more CN losses. In CD-1
mice, chromosome 17 had the most CNV events, and in NMRI mice, chromosome 3 had
the most CNV events. The length of the chromosome did not correlate to the number of
CNVs on that chromosome.
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Including the X chromosome, CNVs across all samples affect 9.2 and 4.1% of the
genome in CD-1 and NMRI mice. In CD-1 and NMRI mice, 80.7 and 89.6% of the CNV
events contained or shared an overlapping region with a gene. When broken down into
copy number states, CNV events that contained or shared an overlapping region with a
gene were 43.3 and 60.7% CN complete losses, 70.8 and 90.2% CN partial losses, and 80.6
and 97.9% CN gains in CD-1 and NMRI mice, respectively.

Figure 2.10: Length of CNV gains and losses across the autosomes in both
outbred mouse stocks. Distribution of lengths of CNV events in CD-1 mice (n = 99)
and NMRI mice (n = 279) across the autosomes. CD-1 mice have more shorter CNVs,
both CN losses and CN gains. CD-1 gains show a bimodal distribution of lengths.
Overall, the landscape of CNVs differs in CD-1 and NMRI mice in terms of length
of CNVs, loss-gain ratio, copy number state and the percentage of CNVs the contain or
share an overlapping region with a gene. Both stocks have a positive correlation between
increasing autosome heterozygosity and the number of CNVs per autosome, indicating
possible evidence for HI. To further investigate HI in the genomes of these mice, specific
chromosomal regions with clusters of high levels of heterozygosity must be examined for
their spatial distribution in regards to copy number variants.
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Recurrent CNVs were identified on all autosomes and the
X chromosome in CD-1 and NMRI mice, with
identification of CNVRs unique to one stock and CNVRs
shared between the two stocks

Towards further characterizing the CNV landscape in the genomes of CD-1 and NMRI
mice, HD-CNV was used to detect recurrent CNV regions and unique CNVs on the
autosomes (Table 2.4) and X chromosome (Table 2.5). 9.57 and 3.95% of CNVs were
unique in CD-1 and NMRI mice, respectively. HD-CNV graph files were portrayed as a
karyotype of recurrent and unique CNV events on the autosomes and X chromosomes of
the CD-1 mice and NMRI mice. These karyotypes were combined to compare CD-1 and
NMRI mice (Figure 2.11).
Table 2.4: Number of unique and recurrent CNVs on the autosomes.
Stock
CD-1
NMRI

CNV Occurrence
Recurrent a Unique
1536
154
3774
160

b

Unique / recurrent ratio
0.10
0.04

a

Recurrent CNVs share a 40% or greater sequence overlap
between CNV calls in individual mouse samples, as detected
by HD-CNV.
b
Unique CNVs only occur in one mouse.
Table 2.5: Number of unique and recurrent CNVs on the X chromosome.
Stock
CD-1
NMRI
a

CNV Occurrence
Recurrent a Unique
94
2
374
4

b

Unique / recurrent ratio
0.02
0.01

Recurrent CNVs share a 40% or greater sequence overlap
between CNV calls in individual mouse samples, as detected
by HD-CNV.
b
Unique CNVs only occur in one mouse.
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Figure 2.11: HD-CNV graph files visualized as a karyotype of recurrent and unique CNV events on the autosomes
in CD-1 (n = 99) and NMRI (n = 279) samples and the X chromosome in male CD-1 (n = 43) and NMRI
(n = 279) mice. The size of each circle is relative to the number of CNV events on that chromosome. A CNV event is
represented as a node, which is depicted as one dot in the heatmap. Edges are lines connecting nodes if the two CNVs present a
genomic overlap greater than 40%. Red represents a higher number of overlaps, while blue represents unique CNVs. Differences
can be seen between the number of CNVs per chromosome and the number of recurrent and unique CNVs in CD-1 and NMRI
mice.
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A CNV-LP was used to depict CNV events at their respective genomic location by
their copy number state (gain, partial loss or complete loss) per individual mouse sample
(Figure 2.12; Appendix 2G). Eleven unique CNVRs were identified - nine in CD-1 mice
and two in NMRI mice, and six CNVRs were shared in both stocks. Unique CNVRs in
CD-1 mice are found on chromosomes 2, 3, 9, 10, 14 and 18, whereas unique CNVRs
in NMRI mice are found on chromosomes 3 and 5. The shared CNVRs are found on
chromosomes 1, 2, 5, 11, 17 and the X chromosome.
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NUID⌧0000⌧0076⌧7650
NUID⌧0000⌧0076⌧7649
NUID⌧0000⌧0076⌧7648
NUID⌧0000⌧0076⌧7647
NUID⌧0000⌧0076⌧7646
NUID⌧0000⌧0076⌧7644
NUID⌧0000⌧0076⌧7643
NUID⌧0000⌧0076⌧7642
NUID⌧0000⌧0076⌧7641
NUID⌧0000⌧0076⌧7640
NUID⌧0000⌧0076⌧7639
NUID⌧0000⌧0076⌧7638
NUID⌧0000⌧0076⌧7637
NUID⌧0000⌧0076⌧7636
NUID⌧0000⌧0076⌧7635
NUID⌧0000⌧0076⌧7634
NUID⌧0000⌧0076⌧7633
NUID⌧0000⌧0076⌧7632
NUID⌧0000⌧0076⌧7631
NUID⌧0000⌧0076⌧7630
NUID⌧0000⌧0076⌧7628
NUID⌧0000⌧0076⌧7627
NUID⌧0000⌧0076⌧7626
NUID⌧0000⌧0076⌧7625
NUID⌧0000⌧0076⌧7624
NUID⌧0000⌧0076⌧7623
NUID⌧0000⌧0076⌧7622
NUID⌧0000⌧0076⌧7621
NUID⌧0000⌧0076⌧7620
NUID⌧0000⌧0076⌧7619
NUID⌧0000⌧0076⌧7618
NUID⌧0000⌧0076⌧7617
NUID⌧0000⌧0076⌧7616
NUID⌧0000⌧0076⌧7615
NUID⌧0000⌧0076⌧7614
NUID⌧0000⌧0076⌧7613
NUID⌧0000⌧0076⌧7612
NUID⌧0000⌧0076⌧7611
NUID⌧0000⌧0076⌧7610
NUID⌧0000⌧0076⌧7609
NUID⌧0000⌧0076⌧7608
NUID⌧0000⌧0076⌧7607
NUID⌧0000⌧0076⌧7606
NUID⌧0000⌧0076⌧7605
NUID⌧0000⌧0076⌧7604
NUID⌧0000⌧0076⌧7603
NUID⌧0000⌧0076⌧7602
NUID⌧0000⌧0076⌧7601
NUID⌧0000⌧0076⌧7600
NUID⌧0000⌧0076⌧7599
NUID⌧0000⌧0076⌧7598
NUID⌧0000⌧0076⌧7597
NUID⌧0000⌧0076⌧7596
NUID⌧0000⌧0076⌧7595
NUID⌧0000⌧0076⌧7594
NUID⌧0000⌧0076⌧7593
NUID⌧0000⌧0076⌧7592
NUID⌧0000⌧0076⌧7591
NUID⌧0000⌧0076⌧7590
NUID⌧0000⌧0076⌧7589
NUID⌧0000⌧0076⌧7587
NUID⌧0000⌧0076⌧7586
NUID⌧0000⌧0076⌧7585
NUID⌧0000⌧0076⌧7584
NUID⌧0000⌧0076⌧7583
NUID⌧0000⌧0076⌧7582
NUID⌧0000⌧0076⌧7581
NUID⌧0000⌧0076⌧7580
NUID⌧0000⌧0076⌧7579
NUID⌧0000⌧0076⌧7578
NUID⌧0000⌧0076⌧7577
NUID⌧0000⌧0076⌧7576
NUID⌧0000⌧0076⌧7575
NUID⌧0000⌧0076⌧7574
NUID⌧0000⌧0076⌧7573
NUID⌧0000⌧0076⌧7572
NUID⌧0000⌧0076⌧7571
NUID⌧0000⌧0076⌧7570
NUID⌧0000⌧0076⌧7569
NUID⌧0000⌧0076⌧7568
NUID⌧0000⌧0076⌧7567
NUID⌧0000⌧0076⌧7566
NUID⌧0000⌧0076⌧7565
NUID⌧0000⌧0076⌧7564
NUID⌧0000⌧0076⌧7563
NUID⌧0000⌧0076⌧7561
NUID⌧0000⌧0076⌧7560
NUID⌧0000⌧0076⌧7559
NUID⌧0000⌧0076⌧7558
NUID⌧0000⌧0076⌧7557
NUID⌧0000⌧0075⌧2257
NUID⌧0000⌧0075⌧2256
NUID⌧0000⌧0075⌧2255
NUID⌧0000⌧0075⌧2254
NUID⌧0000⌧0075⌧2253
NUID⌧0000⌧0075⌧2252
NUID⌧0000⌧0075⌧2251
NUID⌧0000⌧0075⌧2250
NUID⌧0000⌧0075⌧2249
NUID⌧0000⌧0075⌧2248

CNV State
Complete Loss
CNV
State
Partial
Loss
Complete Loss
Gain
Gain
Partial Loss

150

100

20
40
60
0

50

20
40
60
80

25
50
75
100
0
25
50
75

25
50
75
100

25
50
75
100
125

25
50
75
100

0
25
50
75
100
125
30
60
90

50

100

25
50
75
100
125

50

150
0
30
60
90
120

100

50

150
0

100

50

150

100

80

40

160
0

120

80

40

160

120

50

150

100

200

50

150

NMRI
NMRI

100

Mouse Sample ID

CD1
CD-1

SNP_mDIV_D9⌧SNP09_360_111109
SNP_mDIV_D9⌧SNP09_316_102709
SNP_mDIV_D8⌧SNP09_359_111109
SNP_mDIV_D8⌧SNP09_315_102709
SNP_mDIV_D7⌧SNP09_358_111109
SNP_mDIV_D7⌧SNP09_314_102709
SNP_mDIV_D6⌧SNP09_357_111109
SNP_mDIV_D6⌧SNP09_313_102709
SNP_mDIV_D5⌧SNP09_356_111109
SNP_mDIV_D5⌧SNP09_312_102709
SNP_mDIV_D4⌧SNP09_355_111109
SNP_mDIV_D4⌧SNP09_311_102709
SNP_mDIV_D3⌧SNP09_354_111109
SNP_mDIV_D3⌧SNP09_310_102709
SNP_mDIV_D2⌧SNP09_353_111109
SNP_mDIV_D2⌧SNP09_309_102709
SNP_mDIV_D11⌧SNP09_362_111109
SNP_mDIV_D11⌧SNP09_318_102709
SNP_mDIV_D10⌧SNP09_377_102109
SNP_mDIV_D10⌧SNP09_361_111109
SNP_mDIV_D10⌧SNP09_317_102709
SNP_mDIV_D1⌧SNP09_352_111109
SNP_mDIV_D1⌧SNP09_308_102709
SNP_mDIV_C9⌧SNP09_349_111109
SNP_mDIV_C9⌧SNP09_305_102709
SNP_mDIV_C8⌧SNP09_348_111109
SNP_mDIV_C8⌧SNP09_304_102709
SNP_mDIV_C7⌧SNP09_347_111109
SNP_mDIV_C7⌧SNP09_303_102709
SNP_mDIV_C6⌧SNP09_346_111109
SNP_mDIV_C6⌧SNP09_302_102709
SNP_mDIV_C5⌧SNP09_345_111109
SNP_mDIV_C5⌧SNP09_301_102709
SNP_mDIV_C4⌧SNP09_344_111109
SNP_mDIV_C4⌧SNP09_300_102709
SNP_mDIV_C3⌧SNP09_343_111109
SNP_mDIV_C3⌧SNP09_299_102709
SNP_mDIV_C2⌧SNP09_342_111109
SNP_mDIV_C2⌧SNP09_298_102709
SNP_mDIV_C11⌧SNP09_351_111109
SNP_mDIV_C11⌧SNP09_307_102709
SNP_mDIV_C10⌧SNP09_350_111109
SNP_mDIV_C10⌧SNP09_306_102709
SNP_mDIV_C1⌧SNP09_341_111109
SNP_mDIV_C1⌧SNP09_297_102709
SNP_mDIV_B9⌧SNP09_338_111109
SNP_mDIV_B9⌧SNP09_294_102709
SNP_mDIV_B8⌧SNP09_337_111109
SNP_mDIV_B8⌧SNP09_293_102709
SNP_mDIV_B7⌧SNP09_336_111109
SNP_mDIV_B7⌧SNP09_292_102709
SNP_mDIV_B6⌧SNP09_335_111109
SNP_mDIV_B6⌧SNP09_291_102709
SNP_mDIV_B5⌧SNP09_334_111109
SNP_mDIV_B5⌧SNP09_290_102709
SNP_mDIV_B4⌧SNP09_333_111109
SNP_mDIV_B4⌧SNP09_289_102709
SNP_mDIV_B3⌧SNP09_332_111109
SNP_mDIV_B3⌧SNP09_288_102709
SNP_mDIV_B2⌧SNP09_331_111109
SNP_mDIV_B2⌧SNP09_287_102709
SNP_mDIV_B11⌧SNP09_340_111109
SNP_mDIV_B11⌧SNP09_296_102709
SNP_mDIV_B10⌧SNP09_339_111109
SNP_mDIV_B10⌧SNP09_295_102709
SNP_mDIV_B1⌧SNP09_330_111109
SNP_mDIV_B1⌧SNP09_286_102709
SNP_mDIV_A9⌧SNP09_327_111109
SNP_mDIV_A9⌧SNP09_283_102709
SNP_mDIV_A9_SNP09_387_111709
SNP_mDIV_A8⌧SNP09_326_111109
SNP_mDIV_A8⌧SNP09_282_102709
SNP_mDIV_A8_SNP09_386_111709
SNP_mDIV_A7⌧SNP09_325_111109
SNP_mDIV_A7⌧SNP09_281_102709
SNP_mDIV_A7_SNP09_385_111709
SNP_mDIV_A6⌧SNP09_324_111109
SNP_mDIV_A6⌧SNP09_280_102709
SNP_mDIV_A6_SNP09_384_111709
SNP_mDIV_A5⌧SNP09_323_111109
SNP_mDIV_A5⌧SNP09_279_102709
SNP_mDIV_A5_SNP09_383_111709
SNP_mDIV_A4⌧SNP09_322_111109
SNP_mDIV_A4⌧SNP09_278_102709
SNP_mDIV_A4_SNP09_382_111709
SNP_mDIV_A3⌧SNP09_321_111109
SNP_mDIV_A3⌧SNP09_277_102709
SNP_mDIV_A3_SNP09_381_111709
SNP_mDIV_A2⌧SNP09_320_111109
SNP_mDIV_A2⌧SNP09_276_102709
SNP_mDIV_A2_SNP09_380_111709
SNP_mDIV_A11⌧SNP09_329_111109
SNP_mDIV_A11⌧SNP09_285_102709
SNP_mDIV_A10⌧SNP09_328_111109
SNP_mDIV_A10⌧SNP09_284_102709
SNP_mDIV_A10_SNP09_388_111709
SNP_mDIV_A1⌧SNP09_319_111109
SNP_mDIV_A1⌧SNP09_275_102709
SNP_mDIV_A1_SNP09_379_111709

Mouse sample ID
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Genome Position (Mb)

Genome position (Mb)

Figure 2.12: Distribution of CNV events across the autosomes in CD-1 and (n
= 99) NMRI (n = 279) mice and the X chromosome in male CD-1 (n = 43)
and NMRI (n = 279) mice. Different colours represent the state of CNV events,
specifically complete loss (state 0; red), partial loss (state 1; yellow), and gains (states
3 and 4; blue). Unique CNVRs in CD-1 mice are found on chromosomes 2, 3, 9, 10, 14
and 18. Unique CNVRs in NMRI mice are found on chromosomes 3 and 5. The shared
CNVRs are found on chromosomes 1, 2, 5, 11, 17 and the X chromosome.
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Enrichment of immune-related and metabolic pathways
and terms in genes encompassed by or overlapping a CNV
and CNVRs in CD-1 and NMRI mice

To finish the characterization of CNVs in CD-1 and NMRI mice as detected in this
chapter, the genic content of CNVs was analyzed. Galaxy identified 1220 genes in CD-1
mice and 1793 genes in NMRI mice encompassed or overlapped by a CNV (Appendix
2H). The most common genic CNVs and CNVRs in CD-1 mice are summarized in Table
2.6, in NMRI mice in Table 2.7, and in both CD-1 and NMRI mice in Table 2.8.
Metascape identified 40 and 68 enriched terms for CD-1 and NMRI mice, respectively.
The top enriched terms for complete losses are humoral immune response (2.51x10−4 ) in
CD-1 mice, and there were no enriched terms in NMRI mice. The top enriched terms for
partial losses were ‘flavonoid glucuronidation’ (9.77x10−23 ) and ‘antigen processing and
presentation of peptide antigen’ (3.89x10−16 ) in CD-1 and NMRI mice. The top enriched
terms for gains were ‘lymphocyte-mediated immunity’ (9.33x10−26 ) and ‘phagocytosis,
recognition’ (1.0x10−66 ) in CD-1 and NMRI mice.
The Gene Ontology Resource identified 114 and 201 GO terms for CD-1 and NMRI
mice, respectively (Appendix 2I). The top GO term for complete loss CNVs is ‘humoral
immune response’ (2.38x10−4 ) and ‘cell surface receptor signalling pathway’ (1.69x10−7 )
for CD-1 mice and NMRI mice. The top GO term for partial loss CNVs is ‘xenobiotic
glucuronidation’ (3.55x10−16 ) for CD-1 mice and ‘antigen processing and presentation of
peptide antigen’ (4.30x10−13 ). The top GO term for gain CNVs is ‘positive regulation of
immune response’ (1.82x10−20 ) and ‘humoral immune response mediated by circulating
immunoglobin’ (3.52x10−55 ) for CD-1 and NMRI mice.
DAVID identified 27 and 64 KEGG pathways in CD-1 and NMRI mice, respectively
(Appendix 2J). The most common pathways seen in CD-1 and NMRI mice in CNV events
that were partial losses were metabolism pathways. In CN gains, the most common
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pathways seen in both stocks were disease pathways and immune system pathways.
PANTHER identified 10 and 12 enriched terms for CD-1 and NMRI mice, respectively
(Appendix 2K). The top enriched terms in CD-1 mice were ‘angiogenesis’ (1.35x10−3 ),
‘nicotine degradation’ (3.86x10−4 ) and ‘endogenous cannabinoid signalling’ (7.31x10−3 )
for complete losses, partial losses and gains, respectively. No terms were enriched for
complete losses or gains in NMRI mice. The top enriched pathway for partial losses in
NMRI mice was ‘gonadotropin-releasing hormone receptor pathway.’

Genomic location

CN state

1:88205703–88306778

Loss

Number of
mice affected
58

2:24657205–24825055
2:71814473–71856719
3:33800207–33804912
3:121988501–122024550
5:7024671–7048239
10:22148501–22404734

Both
Both
Gain
Gain
Loss
Both

61
60
52
55
69
51

14:81373274–81807414
17:30456718–30924641

Gain
Both

69
76

18:57656600–57739153

Gain

89

X:169953985–169990786

Gain

90

Gene symbol (gene type)*
Hjurp (pc), Mroh2a (pc), Trpm8 (pc), Ugt1a1 (pc),
Ugt1a8 (pc), Ugt1a6a (pc), Ugt1a5 (pc), Ugt1a7c (pc),
Ugt1a2 (pc), Ugt1a6b (pc), Gm20528 (ncRNA), Ugt1a9
(pc), Ugt1a10 (pc), Dnajb3 (pc)
Gm13459 (ps), Cacna1b (pc), Ehmt1 (pc)
Itga6 (pc)
Ttc14 (pc)
Arhgap29 (pc)
Zfp804b (pc)
Gm4895 (ps), Gm26528 (ps), C920009B18Rik (lncRNA),
Gm5421 (ps), Gm34656 (lncRNA), Gm10825 (lncRNA),
E030030I06Rik (pc), Raet1e (pc), Gm1972 (ps), Gm26581
(lncRNA), Raet1d (pc), Gm34607 (lncRNA), H60b (pc),
Gm26740 (lncRNA), 4930444G20Rik (pc), Gm19791 (ps),
Gm7678 (ps), Gm2539 (ps)
Gm19311 (ps), Gm41219 (lncRNA)
Gm9874 (pc), Gm8373 (ps), 1700097N02Rik (lncRNA),
Gm24661 (snRNA), Glo1 (pc), Gm41561 (lncRNA),
Dnah8 (pc), Btbd9 (pc), H2-Ab1 (pc), H2-Aa (pc), H2-Eb1
(pc), Glp1r (pc), Gm20513 (lncRNA)
Gm26038 (snRNA), Gm44491 (miRNA), Gm30636
(lncRNA)
G530011O06Rik (lncRNA), Gm15247 (lncRNA),
Gm15726 (lncRNA), Mid1 (pc)
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Table 2.6: Most common CNVs and CNVRs in CD-1 mice

*

Gene type: Protein coding (pc), pseudogene (ps), non-coding RNA (ncRNA), long non-coding RNA (lncRNA),
microRNA (miRNA)
53

Genomic location

CN state

1:88205703–88306778

Loss

2:77875006–78021364
3:74289954–74407866
3:7511220–76164831

Both
Loss
Loss

3:106114046–106309539

Loss

4:112071427–112626691

Gain

5:3259208–3408118

Loss

5:36505037–36545077
6:41043394–41163544

Both
Loss

6:130222754–130315058

Gain

54

Number Gene symbol (gene type)*
of mice
affected
214
Hjurp (pc), Mroh2a (pc), Trpm8 (pc), Ugt1a1 (pc), Ugt1a8
(pc), Ugt1a6a (pc), Ugt1a5 (pc), Ugt1a7c (pc), Ugt1a2 (pc),
Ugt1a6b (pc), Gm20528 (ncRNA), Ugt1a9 (pc), Ugt1a10 (pc),
Dnajb3 (pc)
90
Gm13727 (ncRNA), Gm13726 (ps), Cwc22 (pc)
99
Gm37050 (ps), Gm6098 (ps)
119
Platr10 (lncRNA) Gm25846 (snoRNA), Gm29133 (pc), Serpini1 (pc), Gm37685 (lncRNA), Gm18428 (ps), Gm37256
(lncRNA), Golim4 (pc), Fstl5 (pc)
57
Gm43709 (ps), Chil3 (pc), Chia1 (pc), Chil4 (pc), Gm6522
(ps)
59
Gm12820 (ps), Gm12815 (ps), Gm12821 (ps), Skint4 (pc),
Skint3 (pc), Skint9 (pc), Gm12819 (ps), Skint2 (pc), Gm24099
(snRNA), Gm12814 (ps)
99
Cdk6 (pc), Gm29868 (lncRNA), Gm36470 (lncRNA),
Gm36548 (lncRNA)
119
Tbc1d14 (pc), Gm32528 (lncRNA)
79
Trbv3 (gs), Trbv5 (gs), Trbv6 (psgs), Trbv9 (psgs), Trbv16 (gs),
Trbv2 (gs), Trbv4 (gs), Trbv7 (psgs), Trbv10 (psgs), Trbv17
(gs), Trbv8 (psgs), Trbv11 (psgs), Trbv12-2 (gs), Trbv12-1
(gs), Trbv13-2 (gs), Trbv13-1 (gs), Trbv14 (gs), Trbv12-3
(psgs), Trbv13-3 (gs), Trbv15 (gs), 5830405F06Rik (lncRNA),
Gm37610 (lncRNA), Tcrb (cc)
66
Klra10 (pc), Gm24072 (snRNA), Klra7 (pc), Klra3 (pc),
Klra13-ps (ps)
Continued on next page
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Table 2.7: Most common CNVs and CNVRs in NMRI mice

11:71142229–71285515
11:93158030–93160977
17:30456718–30924641

17:36017266–36325814

X:169953985–169990786
*

Table 2.7 – continued from previous page
CN state Number Gene symbol (gene type)*
of mice
affected
Both
103
Gm23266 (snoRNA), Nlrp1a (pc), Gm23311 (snoRNA),
Gm30219 (lncRNA), Nlp1c-ps (ps), Nlrp1b (pc)
Loss
85
Car10 (pc)
Loss
62
Gm9874 (pc), Gm8373 (ps), 1700097N02Rik (lncRNA),
Gm24661 (snRNA), Glo1 (pc), Gm41561 (lncRNA), Dnah8
(pc), Btbd9 (pc), H2-Ab1 (pc), H2-Aa (pc), H2-Eb1 (pc), Glp1r
(pc), Gm20513 (lncRNA)
Loss
134
H2-T22 (pc), H2-T23 (pc), Trim71 (pc), Gm20950 (ps),
Gm8810 (ps), H2-Bl (ps), Gm8815 (ps), Gm20530 (ps),
H2-T10 (ps), BC023719 (lncRNA), Gm7030 (pc), Gm9574
(ps), Gm20478 (lncRNA), H2-T24 (pc), A930015D03Rik
(lncRNA), 2410017I17Rik (lncRNA), H2-T-ps (ps), Gm6659
(ps), Gm10499 (ps), Gm8909 (pc), Gm17782 (ps), Gm19684
(pc), Gm6034 (pc), H2-T3 (pc), Gm6623 (ps), Gm20495 (ps),
Gm8835 (ps), Gm4246 (ps), Gm20447 (ps), Gm20392 (ps),
Gm10074 (ps), Gm18604 (ps), Gm20545 (ps), Gm29402 (ps),
Gm6633 (ps), Gm4252 (ps), Gm20546 (lncRNA), Trim39 (pc),
Rpp21 (pc), Gm5682 (ps)
Gain
255
G530011O06Rik (lncRNA), Gm15247 (lncRNA), Gm15726
(lncRNA), Mid1 (pc)

Gene type: Protein coding (pc), pseudogene (ps), gene segment (gs), pseudogenic gene segment (psgs), complex
cluster (cc), non-coding RNA (ncRNA), small nucleolar RNA (snoRNA), long non-coding RNA (lncRNA), microRNA
(miRNA)
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Genomic location
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Genomic location

CN state

1:88205703–88306778

Loss

2:77875006–78021364
3:74289954–74407866
3:106114046–106309539

Both
Loss
Both

4:112071427–112626691

Gain

5:36505037–36545077
6:130222754–130315058

Both
Gain

11:71142229–71285515

Both

17:30456718–30924641

Both

Number Gene symbol (gene type)*
of mice
affected
272
Hjurp (pc), Mroh2a (pc), Trpm8 (pc), Ugt1a1 (pc), Ugt1a8
(pc), Ugt1a6a (pc), Ugt1a5 (pc), Ugt1a7c (pc), Ugt1a2 (pc),
Ugt1a6b (pc), Gm20528 (ncRNA), Ugt1a9 (pc), Ugt1a10 (pc),
Dnajb3 (pc)
131
Gm13727 (ncRNA), Gm13726 (ps), Cwc22 (pc)
108
Gm37050 (ps), Gm6098 (ps)
105
Gm43709 (ps), Chil3 (pc), Chia1 (pc), Chil4 (pc), Gm6522
(ps)
Gm12820 (ps), Gm12815 (ps), Gm12821 (ps), Skint4 (pc),
89
Skint3 (pc), Skint9 (pc), Gm12819 (ps), Skint2 (pc), Gm24099
(snRNA), Gm12814 (ps)
125
Tbc1d14 (pc), Gm32528 (lncRNA)
75
Klra10 (pc), Gm24072 (snRNA), Klra7 (pc), Klra3 (pc),
Klra13-ps (ps)
140
Gm23266 (snoRNA), Nlrp1a (pc), Gm23311 (snoRNA),
Gm30219 (lncRNA), Nlp1c-ps (ps), Nlrp1b (pc)
138
Gm9874 (pc), Gm8373 (ps), 1700097N02Rik (lncRNA),
Gm24661 (snRNA), Glo1 (pc), Gm41561 (lncRNA), Dnah8
(pc), Btbd9 (pc), H2-Ab1 (pc), H2-Aa (pc), H2-Eb1 (pc), Glp1r
(pc), Gm20513 (lncRNA)
Continued on next page
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Table 2.8: Most common CNVs and CNVRs in both CD-1 and NMRI mice
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17:36017266–36325814

X:169953985–169990786
*

Table 2.8 – continued from previous page
CN state Number Gene symbol (gene type)*
of mice
affected
Both
136
H2-T22 (pc), H2-T23 (pc), Trim71 (pc), Gm20950 (ps),
Gm8810 (ps), H2-Bl (ps), Gm8815 (ps), Gm20530 (ps),
H2-T10 (ps), BC023719 (lncRNA), Gm7030 (pc), Gm9574
(ps), Gm20478 (lncRNA), H2-T24 (pc), A930015D03Rik
(lncRNA), 2410017I17Rik (lncRNA), H2-T-ps (ps), Gm6659
(ps), Gm10499 (ps), Gm8909 (pc), Gm17782 (ps), Gm19684
(pc), Gm6034 (pc), H2-T3 (pc), Gm6623 (ps), Gm20495 (ps),
Gm8835 (ps), Gm4246 (ps), Gm20447 (ps), Gm20392 (ps),
Gm10074 (ps), Gm18604 (ps), Gm20545 (ps), Gm29402 (ps),
Gm6633 (ps), Gm4252 (ps), Gm20546 (lncRNA), Trim39 (pc),
Rpp21 (pc), Gm5682 (ps)
Gain
345
G530011O06Rik (lncRNA), Gm15247 (lncRNA), Gm15726
(lncRNA), Mid1 (pc)

Gene type: Protein coding (pc), pseudogene (ps), non-coding RNA (ncRNA), small nucleolar RNA (snoRNA),
long non-coding RNA (lncRNA),
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Mutation cluster detection and heterozygous SNP
genotypes-CNV association

To explore HI in the genomes of CD-1 and NMRI mice, the association between chromosomal heterozygosity and CNVs with proximal association to heterozygous SNP loci
was analyzed. A MANOVA test determined that there is a significant difference between
the association in CD-1 and NMRI mice (p = 6.18x10−8 ). The percent heterozygosity
was graphed against the percent of proximal associated CNVs per chromosome, and a
regression line was fitted for each stock individually (Figure 2.13A). When the estimated
coefficients were compared using a Student’s t-test, they were found to be not significantly
different (p = 0.693; Figure 2.13A). A Spearman rank correlation coefficient analysis on
CD-1 and NMRI mice combined indicated there is a positive correlation (Figure 2.13B,
R = 0.45, p = 0.0049) between increased levels of heterozygous SNP loci and proximal
CNVs, identifying evidence supporting HI in the genomes of CD-1 and NMRI mice.

Figure 2.13: Statistical analysis of the occurrence of proximal associations per
autosome and autosomal heterozygosity. A. Distribution of proximal CNVs per
chromosome and average chromosomal heterozygosity for CD-1 and NMRI mice. B.
Spearman rank correlation coefficient analysis of chromosomal heterozygosity and proximal
CNVs in CD-1 and NMRI mice indicates a positive correlation. The value of the correlation
coefficient (R) can vary between -1 and 1, with 0 indicating no association, -1 indicating
a strong negative correlation, and 1 indicating a strong positive correlation.
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To examine the heterozygous landscape at SNP loci in both outbred mouse stocks,
rainfall plots were created. Rainfall plots show clusters of heterozygous SNP genotypes
in the genomes of both CD-1 and NMRI mice (Figure 2.14), with larger clusters of
heterozygous SNP loci in CD-1 mice and larger deserts in NMRI mice. Regions of clustered
heterozygous SNP loci are separated by regions of clustered homozygous SNP loci, creating
a discontinuous landscape of heterozygosity. Different patterns of discontinuous landscapes
are found across different chromosomes (Figure 2.14) and within the same chromosome
(Figure 2.15) when compared within stocks and between stocks.

Figure 2.14: Visualization of heterozygous SNP genotypes across the genome
though chromosomal position and distance between consecutive heterozygous
SNPs. Comparison of the distribution of heterozygous SNP genotypes in CD-1 mice (A,
B, C) and NMRI mice (D, E, F) on chromosomes 3 (A, D), 5 (B, E) and 11 (C, F). All
chromosomes display a discontinuous landscape of heterozygosity, with differences in the
landscape between chromosomes and outbred mouse stock. A discontinuous landscape
is characterized by regions of clustered heterozygosity separated by regions of clustered
homozygosity. Rainfall plots display heterozygous SNPs at their respective genomic
location (X-axis) against the distance from their neighbouring heterozygous SNP plotted
on a logarithmic scale (Y-axis). SNP loci shown in these rainfall plots are only those
assayed by the array and heterozygous.
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Figure 2.15: The discontinuous landscapes of heterozygosity at SNP loci on
chromosome 17 in six different mice show the inter-animal and inter-stock
differences in landscapes, ideal for studying HI. Comparison of the discontinuous
landscapes of heterozygous SNP loci in CD-1 mice (A, B, C) and NMRI mice (D, E, F)
on chromosome 17. A discontinuous landscape is characterized by regions of clustered
heterozygosity separated by regions of clustered homozygosity. When comparing rainfall
plots it is clear to see there are differences in consecutive heterozygosity and homozygosity
within CD-1 mice (A, B, C) and NMRI mice (D, E, F) and between the landscapes in each
stock. Differences include number of heterozygous clusters and size of homozygous regions
interspersed between heterozygous clusters. Rainfall plots display heterozygous SNPs at
their respective genomic location (X-axis) against the distance from their neighbouring
heterozygous SNP plotted on a logarithmic scale (Y-axis). SNP loci shown in these
rainfall plots are only those assayed by the array and heterozygous.
To examine the spatial association between heterozygosity and CNVs and test for
indirect evidence supporting HI, rainbow plots and J statistic plots were used. Rainbow
plots show a potential association between heterozygous SNP genotypes and CNVs, which
was confirmed using the J function (Figure 2.16). All rainfall, rainbow and J statistic
plots for CD-1 and NMRI mice can be found in Appendix 2L. CD-1 and NMRI mice
have 41.0 and 21.8% of chromosomes that contained CNVs displaying heterozygous SNP
genotypes with proximally associated CNVs. Chromosome 17 contains more CNVs with
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proximal spatial distribution than either both or distal spatial distributions in CD-1 and
NMRI mice. Chromosome 4 in CD-1 mice and chromosome 6 in NMRI mice also contains
more CNVs with the proximal distribution. The majority of CNV events on chromosomes
5, 8, 9, 10, 12, and 13 in CD-1 mice and chromosome 14 in NMRI mice have proximally
distributed heterozygous SNPs. Overall, indirect evidence supporting HI in the genomes

J function

Interlocus Distance (10n bp)

of CD-1 and NMRI mice is detected across multiple autosomes.

Chromosome Distance (107 bp)

Chromosome Distance (bp)

Chromosome Distance (107 bp)

J function

Interlocus Distance (10n bp)

Chromosome Distance (bp)

Figure 2.16: Visualization of the proximal association of heterozygous SNP
genotypes and CNVs on the autosomal chromosomes in CD-1 (top row) and
NMRI (bottom row) mice. Rainbow and J statistic plots were generated to display
the heterozygosity and CNVs on a single chromosome. Rainbow plots display the CNVs in
red dots along the X-axis of the graph at their respective chromosomal position, whereas
black circles represent heterozygous SNPs. The closer these black dots are plotted to the
x-axis, the closer they are to the CNV along the genomic sequence (proximal). J function
statistically analyzes the spatial distribution of the heterozygous SNP genotypes to the
closest CNV. After running 1000 simulations, J statistic produces blue confidence bands,
and if the J function (black line) crosses the lines, the result is significant.

Chapter 2. Characterization of two stocks of outbred mice

2.4

62

Discussion

This chapter presents indirect evidence of HI in the genomes of CD-1 and NMRI mice
and identifies the need for further study to confirm HI and study potential mechanisms.
Additionally, this chapter presents the most extensive characterization of structural
variants and single nucleotide polymorphisms in two outbred mouse stocks, CD-1 and
NMRI. Pairwise comparisons of genetic distances were calculated for all mice using
heterozygous SNPs or CNVs. CNVs were identified and characterized by location, state,
length, recurrence, genic impact and pathway enrichment. The levels of heterozygosity at
SNP loci were analyzed in both stocks, and the discontinuous landscape of clusters of
heterozygosity was detected. Association between clusters of heterozygosity and CNVs
was detected in both CD-1 and NMRI mice, highlighting the need to analyze the nature
and distribution of the clusters of heterozygous SNP loci to explore possible mutational
mechanisms associated with deletions or duplication creating CNVs.

2.4.1

Levels of heterozygosity at SNP loci in CD-1 and NMRI
mice more closely represent heterozygosity in the human
genome

Both CD-1 and NMRI mice have a higher average level of heterozygosity than inbred mice,
with C57BL/6 mice displaying average heterozygosity of 0.6% per mouse. Comparatively,
CD-1 and NMRI mice better represent the level of heterozygosity seen in humans. In
humans, the average heterozygosity at all SNP loci is between 24.6-28.5% [38], which
is approximately three times greater than the average heterozygosity in CD-1 mice and
approximately five times greater than the average heterozygosity in NMRI mice (Table
2.1). Additionally, pairwise comparisons calculated from SNP genotypes in 344 humans
are between 0.002 and 0.109 [53], which is similar to the SNP genetic distances seen in

Chapter 2. Characterization of two stocks of outbred mice

63

CD-1 (0.009–0.180) and NMRI (0.008–0.110) mice, further indicating that CD-1 and
NMRI mice are good models of the genetic variation seen in the human population, and
much more representative models.

2.4.2

SNP genetic distance better represents relatedness
between mice

CD-1 and NMRI mice both had SNP trees that well represented genetic background
and genetic relatedness, but the CNV trees did not accurately represent the relatedness
displayed in the SNP trees. SNP trees accurately depicting relatedness, with relatedness
being lost in CNV trees, has been previously reported in inbred mice [20, 54]. This
relationship is visualized by comparing the coloured subset of samples in the neighbourjoining trees for SNP and CNV genetic distances. In both SNP trees, the selected samples
share a recent common ancestor and are thus on the same branch of the tree. Looking
at the CNV tree, it is evident that these samples are no longer close to each other on
the tree, and hence the aspect of relatedness appears to be lost. Considering the Mantel
test showed no significant difference between the SNP and CNV trees, relatedness is
not entirely lost but confounded by other factors. This disparity could be due to de
novo CNVs, which would confound the relatedness of individuals [20]. Technical error
may also act as a confounding factor. There are eight probes to call each SNP and
detect either the reference/major (A) or alternative/minor (B) allele. A duplicate probe
for both the sense and antisense strand creates redundancy, and redundant probes are
placed at different locations on the microarray. SNP genotype calls are based on the
relative intensity of one probe location, represented by multiple probes on the microarray,
creating high redundancy. In contrast, CNV calls are based on the increase or decrease of
intensity at three consecutive probes compared to a reference [20, 31]. This leaves more
possibility for technical error, making SNP calls more reliable than CNV calls [20, 54] and
this difference indicates SNPs are a much more accurate method of tracking inheritance
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between individuals.

2.4.3

CD-1 and NMRI mice CNV profiles reported here are
comparable to reported trends in humans, and in inbred,
wildtype and wild-derived mice

Overall, the trends in structural variants seen in this study are comparable to trends seen
in humans and trends reported by Locke et al (2015), but there are notable differences.
CD-1 mice have an average of 17 CNVs per mouse, and NMRI mice have an average of 14
CNVs per mouse, which puts them both within the normal range seen in humans - 12-20
CNVs per human [14, 55]. The ratio of losses to gains of 0.84, 2.25 and 2.92 are reported
for classical inbred, wild-derived and wild-caught mice [20]. CD-1 mice display a ratio
similar to classical inbred mice. In contrast, NMRI mice display a ratio approximately
three times higher than wild-derived and wild-caught mice (Table 4). A similar frequency
of losses was seen in a population affected by founder effects and subsequent inbreeding.
This founder population had losses as 70% of their CNV events [55]. NMRI mice may
have experienced genetic drift associated with small population size when transported to
America and subsequently inbred for 51 generations (Figure 2.1).
Inbred, wild-derived and wild-caught mice contained CNVs that affected 8.15% of the
genome [20], which is similar to the levels observed in CD-1 mice (9.2%) but higher than
the levels in NMRI mice (4.2%). This difference could be explained because NMRI mice
display more CN losses, which tend to be shorter in length due to their higher probability
of being more deleterious than gains. Comparatively, one study reported that 12.0% of
the human genome was affected by copy number variable regions [17]. As previously
reported in inbred, wild-derived, and wild-caught mice, most CNVs – 80.7% in CD-1 mice
and 89.6% in NMRI mice, entirely encompass a gene or partially overlap with a gene [20].
Similar to what is reported in inbred mice [17, 20, 56], CD-1 and NMRI mice displayed a
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lower proportion of CNVs that overlapped or encompassed genes when the CN state was
a partial or complete loss. In humans, it was found that the majority of CNVRs detected
encompassed or overlapped a gene or functional sequences [17].
As previously reported, chromosome length did not correlate with the number of CNVs
seen per chromosome [20, 57], which may be due to different levels of recombination events
and mutation rates across the genome [2]. Recombination hotspots occur throughout the
genome, and thus, some chromosomes may have more recombination events occurring,
leading to more opportunities for CNVs to occur [58].
The average length of CNVs reported in this study is higher than what research
has previously reported. Classical inbred, wild-caught and wild-derived mice had an
average length of 54,037 base pairs [20]. Similarly, a population affected by founder effects
had CNVs with an average length of 52,390 base pairs [55], measured using the same
technologies used in this study. The average length of CNVs is approximately 10,000 base
pairs longer in NMRI mice and approximately 30,000 base pairs longer in CD-1 mice. As
observed previously in inbred mice [17, 20], the average length of deletions was shorter
than the average length of gains.
Overall, the trends in CNVs seen in CD-1 and NMRI mice here are comparable to
trends seen in inbred, wild-derived and wild-caught mice. NMRI is unique in that the
trends seen in CNVs in their genome more closely represent trends seen in the genome
of a human founder population, which differs from the CNV profiles in CD-1, inbred,
wild-derived and wild-caught mice.

2.4.4

Cataloguing unique and recurrent CNVs and copy
number variable regions

The majority of CNV events are recurrent, whereas only a small fraction are unique
CNVs. This result was previously observed in inbred mice [20]. CNVRs were detected
across the genome, similar to CNVR distribution in the human genome [17]. This study
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reports 18 novel CNVRs and eight CNVRs that were previously reported in inbred [20, 54],
wild-derived and wild-caught mice [20], with one of these CNVR overlapping a CNV
which has been previously detected in CD-1 mice [30]. The most common CNVR was
detected at X:169,953,985–169,990,786 in both CD-1 and NMRI mice, followed by the
CNVR at 1:88,205,703–88,306,778. All CNVRs and recurrent CNVs encompassed or
overlapped with one or more genes, except for one region on chromosome 3. The CNVR
at 17:36,017,266-36,325,814 in NMRI mice overlapped or encompassed the most number
of genes (Table 2.8). Multiple of the genes that are encompassed or overlapped by the
CNVR on chromosome 17 are histocompatibility genes. Histocompatibility genes are
highly recombinant, which creates increased opportunity for CNV formation and leads to
a copy number variable region [18, 57]. Four CNVRs identified in CD-1 and NMRI mice
were previously reported in inbred, wild-caught and wild-derived mice [20] at 1:8820570388306778, 4:112071427–112626691, 11:71047723–71124806, and 17:30456718–30924641.
The CNVR detected at 4:112071427–112626691 overlaps Skint4, Skint3, and Skint9, which
are genes that are associated with anxiety and have been previously detected in CD-1
mice [30]. CNVs have been previously reported in inbred mice affecting the Klra locus,
Raet1 genes [54], which were detected in CD-1 and NMRI mice (6:130222754–130315058)
and CD-1 mice (10:22148501–22404734). Finally, the CNVRs detected at 1:88,205,703–
88,306,778 and 2:71,814,473–71,856,719 were previously reported to be found uniquely in
wild-caught M. m. musculus and M. m. domesticus, respectively [20].

2.4.5

Enrichment of pathways and terms that respond to a
changing external environment in genes encompassed by
or overlapping a CNV and CNVRs

For both CD-1 and NMRI mice, the majority of enriched terms were immune-related
or metabolic terms. Metascape, The Gene Ontology Resource, and DAVID identified
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disease and immune system pathways enriched in genes involved in CN gains in CD-1
and NMRI mice, CN partial losses in NMRI mice, and CN complete losses in CD-1
mice. Laboratory mice are bred to study disease phenotypes, possibly explaining why
immune system pathways and GO terms are enriched among the CNVs. Classical inbred
mice showed the same enrichment [20]. In another study of inbred mouse strains, the
top enriched GO terms determined from genes overlapped by CNVs were pheromone
receptor and olfactory receptor-related functions, followed by defence response-related
terms and antigen-binding, processing and presentation related terms [54]. While an
enrichment in olfactory receptor-related functions was not seen in CD-1 or NMRI mice,
the enrichment of defence response-related genes was mirrored in CD-1 and NMRI mice,
and antigen-binding, processing and presentation-related terms were mirrored in NMRI
mice. In humans, an enrichment in immune-related genes overlapped by CNVs was
reported in previous studies [14, 56].
In CD-1 mice, the top Metascape term and GO term for CN partial losses were
‘flavonoid glucuronidation’ and ‘xenobiotic glucuronidation,’ both metabolic terms. In
both CD-1 and NMRI mice, the top enriched terms for CN partial losses identified using
DAVID were metabolic terms. This enrichment in the partial loss of metabolic terms may
represent their adaption to a laboratory diet. Comparatively, a study that found wildtype
mice had enriched metabolism pathways in CN gains, whereas classical laboratory strains
did not [20]. Considering wildtype mice have a more varied, adaptive diet than inbred
and outbred laboratory mice, it is plausible that wildtype mice have needs for a greater
variety of metabolic functions and pathways. Interestingly, the phenotypes conferred by
genetic variants are selected for in response to changing external environments.
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Discontinuous clusters of heterozygosity show proximal
spatial association with CNVs

Similar to the association reported in Arabidopsis and peach plants, this chapter demonstrates that in both CD-1 and NMRI mice, there are examples of an elevated occurrence
of CNVs near regional areas of heterozygosity. These examples present indirect evidence
of HI. MANOVA analysis confirmed a difference between increased heterozygosity and
proximal CNVs in CD-1 and NMRI mice. A Spearman rank correlation coefficient confirmed a positive correlation between increased heterozygosity and increased numbers of
proximal CNVs. Interestingly, when analyzing the proximal associations per autosome
by autosomal heterozygosity for CD-1 and NMRI mice individually, the distribution
showed no correlation. However, when combining data for CD-1 and NMRI mice, a
positive correlation became clear. This indicates that a large range of heterozygosity
may be needed to assess HI accurately. The proximal distribution of heterozygous SNP
genotypes and CNVs was seen globally across the genome. Ten chromosomes displayed
more proximal distribution between the two stocks than distal or both, which shows that
no chromosome is a hotspot for Heterozygote Instability. The only chromosome that
displayed more proximal distribution in both stocks is chromosome 17. Chromosome 17
is where the major histocompatibility complex is located. These genes are responsible
for immune responses and antigen processing and presentation [59]. Duplications and
deletions are common in the major histocompatibility complex to diversify antigen presentation [59]. Considering the proximal distribution of CNVs to localized clusters of
heterozygous SNP loci was detected in both CD-1 and NMRI mice, this indicates support
for HI, and thus, the nature of these clusters should be closely analyzed. Considering
how many mechanisms contribute to the formation of CNVs, it is intuitive that CNVs
occur in other locations across the genome. The fact that evidence was detected for a
proximal association of CNVs with heterozygous regions highlights the need to further
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study potential mutational mechanisms of HI and attributes of heterozygous clusters.
Rainfall plots for both mouse stocks showed discontinuous clusters of heterozygous
SNP loci across chromosomes, with uneven distribution in CD-1 and NMRI mice. NMRI
mice have larger deserts of heterozygous SNP genotypes because of their 51 generations
of inbreeding, which introduced more homozygosity into their genome. CD-1 mice were
only inbred for 15 generations, and thus CD-1 mice have genomes with larger clusters
of heterozygosity [26]. Rainbow plots, along with J function analysis, showed CNVs are
associated with these clusters.
Different levels and patterns of heterozygosity can be seen at the genome-wide level,
the chromosome-specific level, and at regional areas of heterozygosity. Overall, CD-1 mice
have a higher level of genomic heterozygosity at SNP loci and have a greater average
number of CNVs per mouse, 17 CNV calls per mouse in CD-1 mice compared to 14
CNV calls per mouse in NMRI mice. Chromosomes with CNVs located proximally to
heterozygous SNP loci tend to have higher heterozygosity, ranging from 7.8–11.0% and
4.3–9.3% in CD-1 and NMRI mice, respectively. Future studies need to closely examine
the characteristics of regional areas of heterozygosity, including density, length, cluster
patterns, and the number of regions per chromosome. This characterization will allow
more in-depth study into the phenomenon first reported in Arabidopsis [31] and the
potential association between heterozygosity at SNP loci and CNVs in CD-1 and NMRI
mice.
Potential mechanisms for HI-induced mutations differ during meiosis and mitosis.
Potential mechanisms for HI during recombination and meiosis are active as regions of
heteroduplex DNA forms. Repair mechanisms may misidentify heterozygous pairs in the
regions of heteroduplex DNA as DNA mismatches and repair them through mismatch
mediated repair. This repair leads to crossovers and is prone to error and slippage,
introducing mutations like CNVs at heterozygous loci [60]. Additionally, heterozygous
sites can lead to poor pairing during heteroduplex DNA formation, leading to Spo11 -
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mediated double-strand breaks. These double-strand breaks are repaired by non-allelic
homologous recombination, which leads to crossovers with a similar strand of DNA. With
crossovers, proximal repeat sequences can lead to misalignment and formation of CNVs
[6]. A potential mechanism for HI during replication in mitosis and meiosis is fork stalling
and template switching (FoSTeS) related to heterozygosity at SNP loci [61]. Occasionally,
there is decreased coupling between heterozygous loci, which may cause the polymerase
and the replication fork to stall. As the polymerase switches templates to similar region on
a different strand of DNA to avoid the stalled location, insertions, deletions, or duplications
are possible [7]. Additionally, as these mistakes are repaired, there are extra rounds of
replication and increased replication stress which creates opportunity for other mistakes
or slippage.

2.4.7

Study limitations

All evidence supporting HI in this chapter was indirect and associative rather than a direct
test or confirmation. This evidence is a launch point for future researchers exploring HI in
outbred mouse models and to confirm the presented indirect, associative evidence. Future
studies can do this by performing controlled breeding experiments to track the landscape
of heterozygosity and CNV occurrence through multiple generations and characterize the
regions of heterozygosity where CNVs are occurring proximally.
Additionally, alternative mechanisms of CNV formation act as confounding factors
when interpreting the potential evidence of HI proposed in this chapter. CNVs may be
co-localizing near clusters of heterozygous SNP loci, but the heterozygosity may not be
contributing to the development of CNVs. Other mechanisms could be causing CNV
formation near heterozygosity, and future studies must characterize the locations where
CNVs are occurring next to clusters of heterozygosity to elucidate if heterozygous loci
contribute to CNV mechanisms.
When using the mouse diversity genotyping array or other microarray technologies,
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the heterozygous landscape detected is only a sampling of the total heterozygosity within
the genome. While the SNP probes are representative across the genome, there is no
inter-probe heterozygosity information meaning there could be heterozygosity between
the probes that went undetected in this study. Additionally, calling CNVs with probes
can lead to false positive and false negative calls, which can be determined through
confirmation assays. Future studies can improve these limitations by using a method with
more extensive coverage like whole-genome sequencing, which would provide the entire
heterozygous landscape of these mice and allow for CNV detection. This method would
be much more costly than using microarray technology. Additionally, CNVs could be
detected using array comparative genome hybridization.
The greatest limitation of the data in this chapter is that by using publicly available
data, there is no tissue available for the samples used to generate the CEL files accessed
for analysis, and thus it is not possible to confirm mouse-specific CNVs and landscapes
of heterozygosity. While this chapter provided indirect confirmation of specific CNVRs
detected in CD-1 and NMRI mice through previously reported CNVRs in CD-1 mice,
inbred mice, wild-derived mice and wild-caught mice, future research can confirm strainspecific CNVs and CNVRs of greatest interest identified using the CNV-LP through
available CD-1 and NMRI outbred mice. To reconstitute a population study of mutation
landscapes researchers must repeat the population study with CD-1 and NMRI mice.
Tissues could be extracted from this study for internal validation of CNVs detected in
these samples and applied to CNVs detected in this study, confirming strain-specific or
population-specific CNVs.

2.4.8

Future directions

Future research should perform controlled parent-progeny breeding studies with CD-1 and
NMRI mice to track Heterozygote Instability and germline mutations through meiosis in
both male and female gametes over multiple generations of mice. Over the whole genome,
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there will be differences in clusters and deserts of heterozygosity, and by using both
CD-1 and NMRI mice, there will be a large enough spread of heterozygosity to assess for
correlation between clusters of heterozygosity and the occurrence of CNVs. Researchers
will then be able to use DNA from the controlled breeding experiment to study the nature
of the heterozygous clusters - size, density, occurrence, the distance between clusters, and
how different clusters co-localize more frequently with CNV occurrence. Defining a profile
for the heterozygous regions where CNVs occurred more frequently, combined with an
examination of sequence context and proximal heterozygosity landscape will help elucidate
possible mechanisms for CNV occurrence due to HI. Using next-generation sequencing
in combination with array comparative genomic hybridization to study this complex
phenotype at a single base resolution will allow an in-depth definition of heterozygous
clusters, detection of CNVs and detection of other de novo mutations. Additionally,
future studies must perform validation assays to confirm the CNVs and heterozygous
regions within CD-1 and NMRI mice. These validations would be performed through
digital droplet PCR and sequencing using CD-1 and NMRI mouse samples to detect
reproducibility. The goal would be to reproduce what was seen in the publicly available
dataset by detecting strain-specific CNVs and CNVRs. Although the exact mouse samples
are not available for confirmation, other mice in the stock will share similar landscapes
of discontinuous heterozygosity and CNV occurrence. Finally, this experimental plan
looks to assess HI during meiosis in germ cells. Future research must look for evidence of
HI in somatic cells, including stem cells and cancer cells, to evaluate associations of this
phenomenon with typical development, stem cell tissue regeneration and cancer. Once
evidence indicates a possible mechanistic location, repair-deficient mice could be used to
elucidate possible mechanisms of HI-induced mutations.
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Conclusion

This chapter provides examples of an increase of CNVs at regions of localized heterozygosity, supporting the Heterozygote Instability hypothesis through indirect evidence. This
chapter provides the most extensive characterization of CNVs in CD-1 and NMRI mice to
date, with novel reporting of previously unidentified CNVs and CNVRs. The abundance
and diversity of CNVs within and between CD-1 and NMRI mice were characterized
and compared to inbred, wild-derived and wild-caught mice. CD-1 mice had a much
higher ratio of CN gains, whereas NMRI mice had a much higher level of CN partial
losses. While this may be due to founder effects and population bottleneck, it is still
important for researchers to consider these differences when using CD-1 and NMRI mice
to study complex phenotypes. Differences in the CNV landscape of CD-1 and NMRI mice
were identified, including differences in locations of recurrent CNVs, which have different
genic effects. This catalogue of CNVRs will be an essential resource for researchers using
these mice as a proxy for complex phenotypes seen in humans, given the genic nature
of CNVs and their potential relevance to phenotypic studies. This chapter provides
a characterized landscape of heterozygosity at SNP loci, and as predicted, there are
clusters and deserts of heterozygosity creating discontinuous landscapes of heterozygosity
in the genome. Differences were seen in the discontinuous landscapes of heterozygosity
in CD-1 and NMRI genomes, with CD-1 mice having greater clusters of heterozygosity,
as predicted based on breeding records. This chapter identified the tendency for CNVs
to co-localize near clusters of heterozygosity. This chapter uses new visualization and
statistical tools to portray CNV landscapes and portray and assess spatial distribution
and association. Proximal association of CNVs to heterozygosity is demonstrated in both
stocks but more strongly in CD-1 mice, consistent with the breeding history of CD-1
mice. There are larger, more prominent clusters of heterozygous SNPs in CD-1 mice due
to being inbred for a shorter number of generations, which may affect HI and its effect
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on CNV occurrence. Attributes of heterozygous clusters should be characterized in the
future to study this possibility and potential mechanisms further.
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Chapter 3.
Toward characterization of genetic
variation in mouse models of basal
cell carcinoma
3.1

Introduction

Evidence suggests that Heterozygote Instability (HI) is a new mutational mechanism
occurring in meiosis in germ cells. Evidence for HI occurring in mitosis in somatic cells has
not been examined. HI has been demonstrated in germ cells by analyzing heterozygosity
at single nucleotide polymorphism (SNP) loci and small insertions and deletions in
Arabidopsis [1] and peach plants [2] and Chapter 2 presented additional indirect evidence
supporting HI in the genomes of two outbred mouse stocks. Notably, HI has not been
studied in somatic cells and cases of high cell division. Two cases of somatic cells with
high genetic variation and either typical or atypical cell division are stem cells and
cancer. Recent research has identified genetic instability due to heterozygous mutations
in Saccharomyces cerevisiae cancer models and proposed that similar mechanisms may
contribute to genetic instability in human cancer cells [3]. This observation implicates
cancer models as a helpful model for assessing HI with somatic, acquired mutations and a
novel, unstudied potential mechanism for genomic instability and mutation accumulation
in cancer cells.
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Genetic variation is high and dynamic in the epidermis

The normal epidermis has high levels of genetic variation. Researchers tracked somatic
variation in the DNA sequence as keratinocytes proliferated and differentiated, using
a single nucleotide polymorphism (SNP). Individuals with homozygous germline alleles
displayed both homozygous genotypes and the heterozygous genotype sequence in skin
surface scrapings. Additionally, the epidermal samples taken from the same location
showed variation in the sequences at the SNP loci at different times. Thus, the somatic
mutation burden in the epidermis is highly dynamic over time, changing horizontally
across the epidermis and vertically up from the dermal to epidermal layers as the cells
divide (Figure 3.1A) [4], making the epidermis ideal for the study of genetic variation in a
model of high dynamic genetic diversity. In humans, the skin is composed of three major
layers, the epidermis, dermis and hypodermis (subcutaneous layer), with the epidermis
stratified into five layers (Figure 3.1B). Keratinocyte stem cells originate in the stratum
basale and proliferate into differentiated keratinocytes throughout the stratum spinosum,
stratum granulosm, stratum lucidum, and stratum corneum. Terminally differentiated
keratinocytes reside in the stratum corneum, where they are continually shed and are
replaced by differentiated cells as they are pushed to the surface.
Oddly, recent research found that aged, UVB-exposed eyelid epidermal tissues have a
de novo mutation burden with UVB signature mutations comparable to squamous cell
carcinoma, basal cell carcinoma and melanoma and positive selection of mutations in
known cancer driver genes, yet no malignant transformation [5]. To study a tissue with
a similar structure, yet no UVB exposure to act as a mutagen, researchers examined
esophageal epithelium tissue [6]. Interestingly, more cancer-associated mutations had
significant positive selection in esophageal tissue than UVB-exposed eyelid epidermal
tissue. The mutation burden displayed signatures of intrinsic mutational processes and
shared mutations in known esophageal cancer driver genes, yet no detectable malignancy
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Figure 3.1: Dynamics of genetic variation and structure in the skin. A. Mutation
burden in the skin is highly dynamic, and it is changing horizontally across the epidermis,
throughout the depth of the epidermis, vertically through the dermal layers and over time
(four dimensions). B. The epidermis, dermis and hypodermis (subcutaneous) layers make
up the skin, with the epidermis having five unique layers. Created using BioRender.com.
occurred [5, 6]. The combined observations that were seen in the aged, UVB-exposed
epidermal tissue and esophageal epithelium tissue highlight the high level of genetic
variability that is seen in human skin without cancer.

3.1.2

High genetic variation in cancer

Hypotheses regarding genetic variants and cancer initiation focus on the accumulation
of post-zygotic, acquired mutations in the same cell, including driver gene mutations,
which confer a growth advantage to the cell and passenger gene mutations, which confer
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less or no apparent growth advantage [7, 8]. The aggregate of accumulated mutations
in a cell is termed the mutation burden. The mutation burden can provide certain
traits to a cell contributing to carcinogenesis. These traits or hallmarks include: selfsufficiency in growth signals, evading growth suppressors, limitless replicative potential,
evading apoptosis, angiogenesis, tissue invasion and metastasis, genome instability, evading
immune destruction, altering cell metabolism, and tumor enhanced inflammation [9, 10].
As a cell acquires mutations that give a phenotypic advantage over other cells, it will
produce daughter cells with the same advantageous mutations, called clonal expansion.
These daughter cells will compete with other cells in the surrounding microenvironment,
with a strong positive selection for the most advantageous phenotypes. Positive selection
of phenotypes conferred by mutations can be inferred by detecting clonal expansion using
sequencing data, specifically detecting high variant allele fraction with read-depth analysis
of next-generation sequencing data [5, 6].

3.1.3

BCC as a case for the highest genetic variation

Basal cell carcinoma (BCC) is a skin cancer that originates from stem cells in the hair
follicle bulge of the epidermis [11, 12]. BCC provides a unique opportunity to study
HI and other complex phenotypes, considering BCC has one of the highest mutation
burdens of human cancers yet is one of the most benign [5]. Contributing to the genetic
variation in BCC is the genetic instability of carcinogenesis and the high genetic variation
inherent to skin. The mutation burden in basal cell carcinomas is at least 25 to 150
somatic mutations/Mb/cell, compared to anywhere between 1 to 380/Mb in squamous
cell carcinoma, and 0.5 to 200/Mb in melanoma [5]. There is a larger range of mutation
burdens in squamous cell carcinoma and melanoma, but comparatively, BCC has a higher
average mutation burden [5]. A high mutation burden leads to a discontinuous landscape
of mutation burden with hotspots in many genes across the genome and positive selection
for advantageous phenotypes conferred by mutations. The landscape of heterozygosity has
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not been documented and must be characterized. In addition to studying the mutational
mechanisms, like HI, the combined observations in BCC, aged UVB-exposed epidermal
tissue, and esophageal epithelium tissue predict factors in addition to mutations per
se are required for tumor initiation and aggression. These observations highlight the
need for a characterized BCC mouse model to study somatic mutation burdens and
specific mutations previously labelled as driver mutations in more depth to understand
the tumorigenic potential of mutations and mutation burdens.
BCC is the most frequently occurring human cancer and the most common skin
cancer, accounting for 75–85% of all skin cancers [13, 14]. BCC incidence is increasing
due to the increased use of tanning beds and increased sun exposure. BCC incidence is
rising five times faster than other cancers, regardless of ethnicity [15, 16]. UVB is the
primary mutagen; thus, risk increases with prolonged sun exposure and BCC generally
occurs on sun-exposed skin, including the face, hands and forearms [17]. BCC is locally
invasive and rarely metastasizes but recurs at a rate of 50% per five years [18, 19]. Most
treatments are non-specific procedures, including surgery, cryosurgery, photodynamic
therapy, radiation therapy, and topical agents [14]. Due to the locally invasive nature of
BCC tumors and current surgical treatment options, there is often an increase in patient
morbidity [12]. Prevention methods are limited to sun avoidance and physical barriers, as
there is currently little evidence to support sunscreen decreasing the incidence of BCC
[20, 21].
Research has determined aberrant activation of the Hedgehog (Hh) pathway is responsible for BCC initiation [11, 22–26]. The Hh pathway plays a role in embryonic
development and tissue homeostasis in adults (Figure 3.2). Hh signaling is very active
during development — regulating cell differentiation, specification and proliferation, and
then activity decreases with age [27, 28]. In mammals, there are three Hh-related proteins:
Sonic hedgehog (Shh), Indian hedgehog and Desert hedgehog. In the skin, Shh signaling is responsible for maintaining the stem cell population and regulating hair follicle
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development [27]. Hh signaling is regulated by PTCH1 inhibition of SMO. When SHH is
absent, PTCH1 binds to and inhibits SMO, leading to repression of pathway activation.
Active SHH binds to PTCH1, preventing PTCH1 binding to SMO, which enables SMO
to be transported to the cilium. SMO promotes the release of GLI transcription factors,
which are transported to the nucleus and activate transcription. Target genes of the Hh
pathway include cell cycle regulators Cyclin D/E, and Myc, and Gli1, Ptch1, and HIP.
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Figure 3.2: Hedgehog (Hh) pathway: Key oncogenic pathway in BCC. Hh
pathway mediated by PTCH1 inhibition of SMO. When SHH is absent, PTCH1 is free
to bind and inhibit SMO leading to repression of target genes. When SHH is active, it
binds PTCH1, inhibiting it from binding to SMO, which enables SMO to be transported
to the tip of the cilium where it can promote release of GLI transcription factors which
are transported to the nucleus and activate transcription. Figure created using images
from SMART Servier Medical Art and Microsoft PowerPoint.
Mutations leading to constitutive activation of Hh signalling are crucial for BCC
initiation, causing hair follicle disruption and uncontrolled proliferation [11, 22, 29]. These
mutations include gain of function mutations in PTCH1, SUFU, and GLI3, or loss
of function mutations in SMO, SHH, GLI1, GLI2, and KIF7, leading to constitutive
activation [22]. The majority of BCC tumors contain somatic mutations in PTCH1, the
major repressor in the Hh pathway. Somatic mutations in SMO, SUFU, and TP53 are
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known to be important in BCC initiation [23, 26, 28, 30, 31]. While these genes are
the most frequently mutated, research has reported a wide variety of additional genes
mutated in BCC tumors, predicting that mutations in these driver genes are not the only
factor contributing to BCC initiation [23, 31]. A large majority of mutations in these
genes bear the mutation signature of UVB damage, a C to T transition at a dipyrimidine
sequence or a CC to TT double transition [17, 31–33].
While sporadic BCC is most common, there are inherited diseases that increase
predisposition to BCC tumorigenesis. Gorlin syndrome or nevoid basal cell carcinoma
syndrome (NBCCS) is an autosomal dominant disease characterized by the development
of multiple BCCs early in life. NBCCS is primarily caused by mutations in PTCH1,
including frameshift, missense, nonsense, insertions, deletions, and splice-site mutations
[34–36]. Xeroderma pigmentosum (XP) is an autosomal recessive disease characterized by
the development of skin cancers — basal or squamous cell carcinoma, by eight years of
age. Mutations in nucleotide excision repair genes responsible for repairing UV damage
are the primary cause of XP [37, 38].

3.1.4

Mouse models of BCC

Multiple mouse models accurately represent human BCC tumors. The first BCC mouse
models overexpressed Shh [39] or Smo [40], both of which were sufficient for BCC
tumorigenesis in mice. Ptch1+/- mice develop small skin tumors that resemble human
BCC tumors. There is a shift in histologic features with UV radiation, resulting in tumors
that more closely resemble human BCCs and grow more rapidly [41]. Mice overexpressing
Gli1 or Gli2 form multiple sporadic skin tumors that were histologically similar to human
BCCs [11, 42, 43]. Sufu+/- mice develop a skin phenotype similar to those observed
in patients with Gorlin syndrome and had aberrant activation of the Hh pathway [44].
There are now multiple Ptch1 knockout and conditional knockout models used to study
preclinical BCC treatment drugs [45]. Considering PTCH1 mutations in human tumors
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are the most common driver mutations and Ptch1 mouse models most accurately match
the morphology of human BCC [45], Ptch1 mouse models are the best choice for mouse
models representing human BCC tumors. The Jackson Laboratory has five strains of mice
listed as ‘useful for studying cutaneous basal cell carcinoma’: heterozygous Ptch1 mice
(ptc-lacz), overexpressing of human GLI1 (Tg(tetO-GLI1)10Rup), constitutive expression
of Smo (R26SmoM2), overexpression of Shh (ShhcreERT2 ), and a model targeting K14,
one of the potential initiating cells of BCC and squamous cell carcinoma (K14CreERT).
Charles River offers knockout mice for Ptch1 and Sufu, through collaboration with
genOway. Taconic Biosciences has an XP mouse model susceptible to basal cell carcinoma,
squamous cell carcinoma and melanoma formation after UV exposure. It is clear that
there are mouse models of BCC that closely mimic the morphology of human BCC.
However, it is unclear whether the genetic variation in these models represents the same
extent and dynamic seen in human BCC.

3.1.5

Similarities and differences between human and mouse
skin physiology

Similarities and differences between mouse and human skin physiology must be considered
when evaluating mouse skin to represent the human skin. Like human skin, mouse skin is
composed of the epidermis, dermis and subcutaneous layer. Unlike human skin, mouse
skin has an additional muscle layer and is haired [46, 47]. Additional, shared components
in mouse and human skin include keratinocytes, fibroblasts, ECM components - including
collagen and hyaluronan, dermal blood vessels, adipocytes and immune cells [46]. Mouse
skin is much thinner than human skin, with mouse skin having two to three layers of
keratinocytes, while human skin has five to ten layers [46, 47]. A study identified 201
shared skin-associated genes between mouse and human skin, with GO terms associated
with maintaining structure. Differences in enriched GO terms showed human skin has
more genes involved in keratinocyte processes, whereas mouse skin has more genes involved

Chapter 3. Mutagenesis in models of BCC

90

in muscle contraction [46]. While the differences should be taken into account while
analyzing results and applying them to human skin, mouse skin is a valuable model due
to the similarities mentioned above, the abundance of genetic variants with targeted
disruptions in known oncogenic driver pathways, the critical use of UVB to accelerate
tumorigenesis in mouse models and the more intense study of skin physiology in mouse
compared to other mammals. Mouse skin has been important for studying human skin
physiology, wound healing and potential topical treatments. In mice, distinct niches of
stem cells are responsible for renewal in the epidermis. Stem cells in the stratum basale
replenish the interfollicular epidermis, whereas stem cells in the hair follicle bulge are
responsible for renewing the hair follicle and can also replace interfollicular epidermis
when skin is wounded. Hh signalling is responsible for the activation of these bulge stem
cells, and without activation, the stem cells will remain quiescent [48, 49].

3.1.6

Available mouse models of basal cell carcinoma provide
the means to analyze HI in rapidly dividing somatic cells

Given the high levels of genetic variation detected in human skin, cancer and BCC
specifically and the likeness in mouse and human epidermal layers and keratinocyte
development, available mouse models of BCC provide a means to analyze HI in rapidly
dividing somatic cells and explore the mystery of one of the highest mutation burdens
within a benign human cancer. A study analyzing mutations in oncogenes found that
55% of all driver mutations were heterozygous [50] and intuitively, considering the loss
of heterozygosity reported in human BCC tumors [23, 30, 31, 51–54], there will be a
non-random heterozygous landscape in BCC applicable for HI testing. Additionally, CD-1
outbred mice have been crossed with Ptch1neo67/+ mice to create a mouse model of BCC
that develops tumors when exposed to radiation [55, 56]. This breeding will lead to clusters
of heterozygosity in the genome of this BCC mouse model, suitable for the investigation
of HI in somatic cells. Before analyzing potential mutational mechanisms like HI, the
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genomic landscape of heterozygosity in mouse models of BCC must be characterized, and
the level of genetic variation must be compared to the level reported in human BCC. A
characterized model allows the study of HI through localized regions of heterozygosity
and mutations like copy number variants (CNVs). Elucidation of HI in somatic cells
would provide an additional mutational mechanism for cancer researchers to consider
when studying tumorigenesis and mutation burdens in cancer.
Additionally, a characterized mouse model of BCC allows the study of the contributing
factors and mechanisms that sustain BCC as a benign cancer despite a high mutation
burden, applicable to what is seen in aged, UVB exposed eyelid and esophageal tissue.
Characterized mouse models will allow researchers to study mutational mechanisms and the
clonal architecture in mouse BCC tumors and detect and track the dynamic of subclonal
architecture with far more detail than possible in humans. Finally, a characterized model
allows the better evaluation of targeted therapies for treating BCC tumors and suppressing
tumor recurrence.

3.1.7

Research goal and specific objectives

Research goal: To evaluate available mouse models of BCC as proxies for human somatic
diversity and suitability for the study of HI. A systematic literature review was performed
to document the reported genetic variation in human and mouse models of BCC to
determine whether mouse models of BCC reproduce a similar burden and dynamic of de
novo somatic mutations that characterize human BCC tumors. The systematic literature
review revealed a significant gap in knowledge of the genetic variants in mouse BCC
driving the next steps. Thus, the goal is to design an experiment to detect the genetic
variation in mouse models of BCC and propose methods to test HI and the tumorigenic
potential of mutation burdens.
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The specific objectives are:
1. To perform a systematic literature review to compile a database of gene mutations
reported in either or both human and mouse BCC tumors.
2. To compare the extent of the characterization of the reported mutation burden in
both human and mouse BCC to evaluate mouse models of BCC as a proxy to study
HI in the context of somatic cells.
3. To identify enriched terms and pathways using the list of mutated genes reported
in human BCC tumors to establish pathways affected in human BCC tumors.
4. To design tools and pipelines to quantify and analyze the mutation burden in mouse
BCC to fill the knowledge gap and permit the study of HI in a somatic cell model.

3.2
3.2.1

Materials and methods
Systematic literature review

To understand the mutation burden in BCC, a systematic literature review was performed
to compile a database of gene mutations reported in human and mouse BCC tumors.
The data were collected through a series of web searches using PubMed, Google Scholar
and Web of Science to identify research published between January 1990 and April 2020
regarding genes mutated in either human or mouse BCC tumors.
Preliminary search terms were TOPIC:(basal cell carcinoma) AND TOPIC:(mutations),
which gave 1,942 results. From these, the search terms were narrowed into a more
specific set using (TOPIC:(basal cell carcinoma) AND TOPIC:(reported mutations) AND
TOPIC:(human)) NOT TOPIC:(expression) to identify mutations in human tumors and
(TOPIC:(basal cell carcinoma) AND TOPIC:(reported mutations) AND TOPIC:(mouse))
to identify mutations in mouse models of BCC. These searches returned 364 results for

Chapter 3. Mutagenesis in models of BCC

93

human samples and 32 results for mouse samples. Primary research articles were selected,
and studies were included if they reported one or more mutated gene(s) in a tumor
sample from sporadic BCCs, patients with NBCCS, or mouse models of BCC. Study
characteristics and results were tabulated and reported.

3.2.2

Comparison of reported mutations in human and mouse
BCC tumors

To evaluate mouse models of BCC tumors as a proxy for the genetic variation seen in
human BCC tumors and as a proxy to study HI in the context of somatic cells, a list of
genes with reported mutations in human BCC tumors was created and compared to a list
of genes with reported mutations in mouse BCC tumors. A table was created to compile
mutation frequency, base or protein change, and mutation type when available.

3.2.3

Characterization of reported mutations in human and
mouse BCC tumors

To identify pathways affected in human BCC tumors, the list of 110 genes with mutations
reported in human BCC tumors was used to detect enrichment of pathways and GO terms.
The list was input into Metascape for enrichment analysis [57]. Pathway-enrichment
analyses were performed using Protein Analysis Through Evolutionary Relationships
(PANTHER) [58] and the Database for Annotation, Visualization and Integrated Discovery
v6.8 (DAVID), which identifies Kyoto Encyclopedia of Genes and Genomes (KEGG)
[59, 60] pathway enrichment. Gene ontology (GO) Enrichment Analysis was performed
using The Gene Ontology Resource [61, 62]. GO annotations of Biological Processes
(GO BP DIRECT), Molecular Functions (GO MF DIRECT), and Cellular Component
(GO CC DIRECT) were analyzed. Enriched terms were included using a P-value cut-off of
less than 0.05 and were compared to identify similarities and differences between reported
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mutations in human and mouse BCCs.

3.2.4

Experimental design and bioinformatics pipelines

To fill the knowledge gap regarding mutated genes in mouse models of BCC and permit
the study of HI in a somatic cell model, three experimental designs and cost evaluations
were developed and compared for mutation detection by a targeted exome panel, wholeexome sequencing (WES) and RNA-sequencing for 12 mouse samples. Experimental
designs for mutation confirmation by digital droplet PCR (ddPCR) and Sanger sequencing
were also designed. All methods use mm10 as the mouse reference genome, which is
available for download from the Genome Reference Consortium [63]. A next-generation
sequencing (NGS) targeted exome panel was custom-designed for DNA-extracted from
mouse samples using Illumina DesignStudio Software [64]. This program allows the
creation of a panel by selecting genomic regions of interest. All driver genes compiled in
the systematic review were included. For each gene, the 5’ and 3’ untranslated regions
(UTR), promoter, exons, and splice junctions were included for sequencing using the
targeted exome panel. Targeted exome sequencing, WES and RNA-sequencing costs
were determined and compared. Additionally, ddPCR and Sanger sequencing costs were
determined and compared. The best bioinformatics tools for quality control, processing,
alignment, analysis, and visualization steps were compiled into one bioinformatics pipeline
for WES data and targeted exome sequencing data and another for RNA-sequencing data.
ddPCR experimental protocols were designed to detect the copy number of a subgroup of
genes. Sanger sequencing experimental protocols were designed to confirm mutations in a
small subgroup of genes critical to BCC initiation.
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Results
Summary of study characteristics

Between 1990–2020, 62 studies reported one or more mutated gene(s), with 52 studies
reporting mutations detected in human BCC tumors (Table 3.1) and 10 studies examining
genes in mouse models of BCC (Table 3.2). 40 studies examined mutations in patients
with sporadic BCC, 17 studies examined mutations in patients with NBCCS, two studies
examined mutations in patients with advanced or metastatic BCC, and one study examined
mutations in XP patients. Genes reported in mice are the current genes used to model
BCC in mice, which target aberrant activation of the Hh signalling pathway, initiating
tumorigenesis [65].

Literature Data
Year Samples Genes
Occurrence Key Finding
van der Schroeff et al [66] 1990 30
H-ras, N- Sporadic
Missense mutations in codon 12 of H-ras (G-C or G-D)
ras, K-ras
and codon 61 K-ras (E-H) genes
Sporadic, Allelic loss of chromosome 9q31 in 11 sporadic BCC
Gailani et al [67]
1992 19
PTCH1
NBCCS
cases and all hereditary cases
Rady et al [68]
1992 14
TP53
Sporadic
14 mutations, all with UV signatures
Ziegler et al [69]
1993 27
TP53
Sporadic
UV-induced hotspot mutations in TP53
van der Riet et al [70]
1994 36
TP53
Sporadic
Mutations in TP53 and inactivation of one but not
both TP53 alleles
Hahn et al [71]
1996 252
PTCH1
NBCCS
Mutations in PTCH1
Johnson et al [72]
1996 72
PTCH1
Sporadic, Mutations in multiple exons of PTCH1
NBCCS
Gailani et al [73]
1996 37
PTCH1
Sporadic
Mutations in PTCH1
Chidambaram et al [74]
1996 59
PTCH1
NBCCS
Eight new PTCH1 mutations
Unden et al [75]
1996 22
PTCH1
Sporadic, Germline mutations in PTCH1 in three families and
NBCCS
somatic mutations in sporadic BCCs
Lench et al [76]
1997 16
PTCH1
NBCCS
Five novel germline mutations in PTCH1
28 mutations in PTCH1, with 86% of mutations causWicking et al [77]
1997 71
PTCH1
NBCCS
ing protein truncation
Aszterbaum et al [78]
1998 86
PTCH1
Sporadic
Mutations in PTCH1 gene in sporadic BCC and patients with NBCCS
Incidence increased with more TP53 mutations,
Ouhtit et al [79]
1998 128
TP53
Sporadic
CC>TT mutation at codons 247 and 248 associated
with increased risk of BCC
Xie et al [40]
1998 3
SMO
Sporadic
Activating missense mutations in SMO
Lam et al [80]
1999 20
SMO
Sporadic
1604G-T is a mutation hotspot in SMO
Shen et al [51]
1999 20
PTCH1
Sporadic
LOH at 9q22.3 in sporadic BCCs
Continued on next page
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Ratner et al [82]
Kim et al [32]
Lam et al [80]
Couv-Privat et al [83]
Sironi et al [52]
Freier et al [84]
Reifenberger et al [30]
Heitzer et al [85]

Fan et al [86]
Pastorino et al [87]
Fernandes et al [53]
Pan et al [88]

Fujii et al [89]
Huang et al [90]
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Table 3.1 – continued from previous page
Year Samples Genes
Occurrence Key Finding
1999 85
PTCH2
NBCCS
Characterized the genomic structure of PTCH2 and
identified a truncating mutation and a splice site mutation
TP53,
First report of UV-specific TP53 and PTCH1 muta2001 2
Sporadic
PTCH1
tions in the same BCC sample
Sporadic
UV-induced mutations and missense mutations most
TP53,
2002 15
PTCH1
common in TP53 and PTCH1 in Korean patients
2002 3
PTCH1
NBCCS
Three new mutations detected in PTCH1 in probands
of three families
SHH mutations in basal but not squamous cell carci2004 33
SHH
XP
noma
Sporadic
LOH at 4q32-35 spanning ING2 and SAP30
2004 19
ING2,
SAP30
2006 273
NMYC
Sporadic
NMYC copy number gain
2006 42
Multiple
Sporadic
PTCH1, TP53, SMO and SUFU mutations
2007 60
PTCH1
Sporadic
UV signature in most of the PTCH1 mutations and no
difference between mutations in early-onset, regular
and multiple BCCs.
2008 25
PTCH2
NBCCS
Novel mutation in exon 15 of PTCH2 (215G-A)
2009 5
SUFU
NBCCS
First report of a germline SUFU mutation
2010 21
PTCH1
Sporadic
PTCH1 LOH seen more in aggressive BCC
2010 44
PTCH1
Sporadic, Standard two-hit model accounts for 30% of the inNBCCS
activated PTCH1, a one-hit model accounts for 32%
and the remaining cases had no alteration to PTCH1
2013 1
PTCH2
NBCCS
Frameshift mutation in PTCH2 causing NBCCs in a
Chinease family
2013 31
PTCH1
Sporadic
17 of 31 BCCs had PTCH1 mutations, with majority
insertions and deletions
Continued on next page
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Literature Data
Smyth et al [81]

Populo et al [91]
Scott et al [92]

Wang et al [93]

Denisova et al [94]
Martincorena et al [5]

Temel et al [95]
Bonilla et al [23]

Temel et al [96]
Bal et al [97]
Kato et al [98]
Matsudate et al [99]
Goodman et al [100]
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Table 3.1 – continued from previous page
Year Samples Genes
Occurrence Key Finding
2014 12
Multiple
Sporadic
Characterized the mutation landscape and detected a
uniquely high number of mutations per tumor
2014 196
TERT
Sporadic
TERT promoter mutations
2014 42
TERT
Sporadic, Detected TERT promoter mutations in 78% of spoNBCCS
radic BCC tumors and in 68% of tumors from patients
with NBCCS
TP53,
Sporadic
Incidence of UV-specific mutations in TP53 and
2014 30
PTCH1
PTCH1 is much lower in Chinese than in white populations
DPH3,
Sporadic
Frequent DPH3 and OXNAD1 mutations
2015 137
OXNAD1
2015 234
Multiple
Sporadic
Mutation burden in BCC tumors is between 25–150
somatic mutations/Mb/cell with a high prevalence of
C >T mutations
2015 75
ING2
Sporadic
Decreased levels of ING2 expression
2016 293
Multiple
Sporadic
85% of BCCs had mutations in Hh pathway genes and
85% of the BCCs had mutations in additional driver
genes
2016 27
SIRT1-7
Sporadic
Significantly decreased expression levels of SIRT2 and
SIRT3 mRNAs
2017 48
ACTRT1
NBCCS
Germline mutations in ACTRT1 or sequences surrounding ACTRT1.
2017 10
PTCH1
NBCCS
73 mutations in PTCH1 – 10 confirmed to be splicing
mutations that affected the splice donor site
2017 10
Multiple
NBCCS
TES-based methods are better for NBCCS diagnosis
2018 9
Multiple
Advanced, Tumor mutation burden (TMB) and genomic landmetastatic scape of nine samples from advanced or metastatic
basal cell carcinoma patients
Continued on next page
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Literature Data
Jayaraman et al [31]

Maturo et al [102]

Table 3.1 – continued from previous page
Year Samples Genes
Occurrence Key Finding
2019 11
PTCH1
Advanced, Identical PTCH1 nonsense mutations detected in
metastatic primary tumor and metastasis, plus increased UVinduced DNA damage
PTCH1,
Sporadic
Detected and characterized PTCH1, TP53, TERT
2020 191
TP53,
promoter, and DPH3 promoter mutations, with a high
TERT,
proportion being C >T mutations. Hotspot mutations
DPH3
detected in the TERT promoter region

Abbreviations used: Basal cell carcinoma (BCC); Nevoid basal cell carcinoma syndrome (NBCCS); Zeroderma pigmentosum
(XP); Ultraviolet (UV); Tumor protein 53 (TP53 ); Patched (PTCH ); smoothened (SMO); Sonic hedgehog (SHH ); Inhibitor of
Growth Family Member 2 (ING2 ); Sin3a Associated Protein 30 (SAP30 ); Loss of heterozygosity (LOH); Suppressor of Fused
Homolog (SUFU ); Telomerase Reverse Transcriptase (TERT ); Diphthamide Biosynthesis 3 (DPH3 ); Oxidoreductase NAD
Binding Domain Containing 1 (OXNAD1 ); Actin Related Protein T1 (ACTRT1)
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Literature Data
Oro et al [39]
Xie et al [40]
Aszterbaum et al [41]

Year Transgenic Mice
1997 Overexpressing Shh
1998 Overexpressing Smo
1999 Lacking one Ptch1 allele

Genes
Shh
Smo
Ptch1

Key Finding
Overexpression of Shh is sufficient in inducing BCC
Activating mutations in Smo lead to sporadic BCC
Ptch1+/- mice develop follicular neoplasms resembling
human tumors. Exposure to UV- or ionizing-radiation
results in an increased number and size of tumors and
a shift in their histologic features so that they more
closely resemble human BCC.
Nilsson et al [42]
2000 Overexpressing Gli1
Gli1
Overexpression of Gli1 is sufficient for tumor initiation
without mutations in Tp53 or ras
Grachtchouk et al [43] 2000 Conditionally expressing Gli2 Gli2
Overexpressed Gli2 can spontaneously cause BCC
Mancuso et al [55]
2004 One Ptch1 allele inactivated
Ptch1 Characterized a multistep model of BCC development with and without exposure to UV- or ionizingradiation
Hutchin et al [11]
2005 Conditionally expressing Gli2 Gli2
Continued BCC growth requires Hh signaling
Sufu+/- mice develop a skin phenotype similar to GorSvärd et al [44]
2006 Lacking one Sufu allele
Sufu
lin syndrome
Mancuso et al [103]
2006 Lacking one Ptch1 allele
Ptch1 Tumorigenesis is strongly affected by the hair growth
cycle
BCCs arise from long-term resident progenitor cells of
Yousef et al [12]
2010 Conditionally expressing Smo Smo
the interfollicular epidermis and upper infundibulum
Nitzki et al [45]
2012 Conditional Ptch1 knockout
Ptch1 Multiple different models of Ptch1 knockout mice
develop tumors similar to human BCC tumors
Abbreviations used: Basal cell carcinoma (BCC); sonic hedgehog (Shh); smoothened (Smo); patched1 (Ptch1 ); ultraviolet
(UV); GLI Family Zinc Finger 1 (Gli1 ); tumor protein 53 (Tp53 ); GLI Family Zinc Finger 2 (Gli2 ); Suppressor of Fused
Homolog (SUFU )
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3.3.2

Disparity in reported mutation burden in human tumors
and mouse models

A list of 110 genes reported with mutations in human BCC tumors was compiled. Out of
these genes, six were confirmed to be mutated in mouse BCC tumors (Table 3.3). These
six genes are Ptch1, Smo, Shh, Sufu, Gli1 and Gli2. Location of mutation and amino acid
substitution were recorded (Appendix 3A). PTCH1 was the most frequently reported gene
in human and mouse BCC tumors. Inactivating mutations in PTCH1 include missense
mutations, nonsense mutations, insertions, deletions, splice site mutations, UVB signature
mutations, loss of heterozygosity and promoter mutations, with the most common being
nonsense and splice-site mutations. Overall there is no evidence for hotspot mutation
regions in PTCH1 (Figure 3.3). UVB specific mutations were reported in PTCH1, TP53,
SHH, SMO, CRNKL1, NEBL, STAT5B, DPH3 and OXNAD1, with the majority of
mutations in TP53 being C to T transitions. Both PTCH1 and TP53 mutations had a
prevalence of C to T transitions and CC to TT tandem substitutions. Mutation hotspots
in TP53 are at codons 177, 196, and 245. Promoter mutations were detected in DPH3
[94, 102], OXNAD1 [94], and TERT [91, 92, 100, 102].

Figure 3.3: Reported mutations in PTCH1. Exons are represented as blue bars.
Each lollipop represents one point mutation. Mutation data was collected during the
literature review.

Table 3.3: List of genes with reported mutations in human BCC tumors.
Gene
ARID1A*
ACTRT1
ASXL1*

Nature of Mutation
Nonsense
Insertion, substitution
Nonsense

Reference
[23, 100]
[97]
[100]
Continued on next page

102

Chapter 3. Mutagenesis in models of BCC

DPP10
EPHA3*
ERBB2*
ERBB4*
E2F3
FAT1
FBXW7*
FGFR3
FLT1*
GLI1* †

Table 3.3 – continued from previous page
Nature of Mutation
Point mutation
Nonsilent
Nonsense
Copy number gain
Amplification
Missense
Missense, nonsense, point mutation, deletion
Frameshift
Missense, C >T Transition
Nonsilent
Nonsilent
Nonsilent
Missense
Nonsilent
Nonsilent
Substitution (Promoter), CC>TT tandem substitutions
Nonsilent
Missense
Recurrent, missense
Missense
Copy number gain
Point mutation
Deleterious, missense, nonsense
Missense
Missense
Missense

GLI2 †
GLI3
GPR139
GRIN2A*
GRM3*
HEATR7B2
HHIP
HRAS*
ING2
INPP4B*
ITIH2
JAK2*
KCNT2
KDM5A*

Missense
Missense
Nonsilent
Nonsilent
Missense
Nonsilent
Point mutation
Recurrent, substitution
Deletions, LOH
Nonsense
Nonsilent
Amplification
Nonsilent
Missense

Gene
BRAF
C7
CASP8
CCND3
CD274*
CDKN1A*
CDKN2A*
CREBBP*
CRNKL1*
CSMD1
CSMD2
CSMD3
CTNNA1*
DCC
DPCR1
DPH3

Reference
[5]
[31]
[23]
[23]
[100]
[100]
[23, 100]
[100]
[31]
[31]
[31]
[31]
[100]
[31]
[31]
[94, 102]

[31]
[100]
[23]
[100]
[23]
[5]
[23]
[23]
[100]
[12, 26, 30, 99,
100]
[12, 26, 99]
[99]
[31]
[31, 100]
[100]
[31]
[26, 99]
[5, 23]
[52, 95]
[100]
[31, 104]
[100]
[31]
[100]
Continued on next page
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Gene
KDR*
KEAP1*
KEL 1*
KIF7
KNSTRN*
KRAS*
LATS1*
LATS2*
LRP1B*
MAGI2*
MLL2*
NEBL*
NF1
NMYC*
NOTCH1*
NOTCH2*
NOTCH3
NPAP1
NRAS*
OR5M3
OXNAD1
PCDHB2
PCDHB3
PCDHGB3
PDCD1LG2*
PDGFRA*
PIK3CA*
PIK3R1*
PIK3R2*
POM121L12
PPIAL4G
PPP1R3A
PPP6C*
PREX2
PTCH1* †

PTCH2
PTEN*
PTPN14*

Table 3.3 – continued from previous page
Nature of Mutation
Missense
Missense
Missense
Missense
Missense
Recurrent, substitution
Recurrent, missense, nonsense
Missense
Nonsense, splice site
Nonsense
Frameshift
Missense, C >T Transition
Point mutation
Recurrent, CNV (Gain), missense
Missense, nonsense
Nonsense
Point mutation
Nonsilent
Recurrent, substitution
Nonsilent
Substitution (Promoter), CC>TT tandem substitutions
Nonsilent
Nonsilent
Nonsilent
Amplification
Missense
Recurrent
Nonsense
Nonsense
Nonsilent
Missense
Nonsilent
Recurrent, missense
Nonsilent
Missense, truncating, nonsense, InDels, splice site,
C>T transitions, CC>TT transitions, LOH

Truncating, Frameshift, Missense
Splice site
Missense, Truncating

Reference
[100]
[100]
[100]
[99]
[23]
[5, 23]
[23]
[23]
[100]
[100]
[100]
[31]
[5]
[23, 84, 105]
[5, 23, 31, 100]
[5, 23, 31, 100]
[5]
[31]
[5, 23]
[31]
[94]

[31]
[31]
[31]
[100]
[100]
[23]
[100]
[100]
[31]
[23]
[31]
[23]
[31]
[23, 26, 30–32, 51,
53, 67, 71–78, 80,
82, 88, 90, 98–102,
105]
[81, 86, 89, 99]
[100]
[23]
Continued on next page
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Gene
RAC1*
RB1*
RBM10*
RPL22
RUNX1*
SAP30
SHH †
SLIT2*
SMARCA4*
SMO* †
STAG2*
STAT5B*
STEAP4
STK19*
SPTA*
STK36
SUFU* †
SULT1C3
TAF1*
TET2*
TSC1*
TERT*
TGFBR1
TMEM132D
TMEM217
TP53*

UGT2B10
WT1*
YAP1
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Nature of Mutation
Reference
Missense
[23, 100]
Deleterious, truncating, missense, LOH
[23]
Splice site
[5, 100]
Missense
[23]
Missense
[100]
LOH
[52]
Silent, missense, C>T transitions, CC>TT tan- [83, 99]
dem substitutions
Nonsense
[100]
Nonsense
[100]
Missense, silent, C>T transition, CC>TT, G>T [23, 30, 40, 80, 99,
transversion
100]
Nonsense
[100]
Missense, C >T Transition
[31]
Nonsilent
[31, 106]
Recurrent, Missense
[23]
Missense
[100]
Deletion
[99]
Substitution
[23, 99]
Nonsilent
[31]
Splice site
[100]
Frameshift
[100]
Loss
[100]
Substitution (Promoter)
[91, 92, 100, 102]
Deletion
[99]
Nonsilent
[31]
Nonsilent
[31]
Missense, truncating, nonsense, splice site, [5, 23, 31, 32, 68–
frameshift, C>T transitions, CC>TT tandem 70, 79, 82, 100,
substitutions
102, 105]
Nonsilent
[31]
Missense
[100]
Point mutation
[23]

* Mutation location and amino acid substitution recorded in Appendix 3A
†
Gene has been studied in mouse models of BCC
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Analysis of pathway and gene ontology enrichment in reported genes with mutations in BCC tumors

All 110 genes identified in the systematic literature review were input into Metascape,
PANTHER, DAVID and GO Enrichment Analysis. Metascape detected 77 enriched terms,
with the top three enriched terms being ‘Pathways in Cancer’ (1.2x10−35 ), ‘Melanoma’
(4.1x10−29 ) and ‘Regulation of smoothened signalling pathway’ (3.4x10−18 ) (Figure 3.4).
PANTHER analyses reported 33 enriched pathways (Appendix 3B), with the most genes
involved in the ‘Hedgehog signalling pathway’ (1.2x10−12 ), followed by the ‘p53 Pathway
feedback loops2’ (3.0x10−11 ) and ‘EGF receptor signalling pathway’ (7.8x10−10 ). All
genes reported in mouse tumors were in the Hh pathway. KEGG analyses reported 62
enriched pathways (Appendix 3C), with ‘Pathways in cancer’ (2.8x10−20 ) being the most
enriched term followed by other cancers. ‘Hedgehog signalling pathway’ (5.7x10−10 ) is
the first non-cancer enriched term. There was significant enrichment for 1029 Biological
Processes, with the top three enriched terms being ‘regulation of developmental process’
(3.4x10−15 ), ‘regulation of cell population proliferation’ (2.5x10−15 ), and ‘regulation of
smoothened signalling pathway’ (6.6x10−15 ). There was significant enrichment for 44
Molecular Functions, with the top three enriched terms being ‘transcription factor binding’
(5.3x10−5 ), ‘protein kinase activity’ (7.7x10−4 ), and ‘ion binding’ (2.3x10−3 ). There was
significant enrichment for 29 Cellular Component terms, with the top three enriched
terms being ‘nucleoplasm’ (1.9x10−4 ), ‘nucleus’ (2.4x10−4 ), and ‘ciliary tip’ (1.9x10−4 ). A
complete list of enriched terms can be found in Appendix 3D.

3.3.4

Multiple experimental designs provided for
characterization of somatic variation in BCC

It is essential to characterize the mutation burden in available mouse models of BCC to
confirm they are appropriate proxies for the mutation burden and dynamic seen in human
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hsa05200: Pathways in cancer
WP4685: Melanoma
GO:0008589: regulation of smoothened signaling pathway
GO:0007507: heart development
GO:0040008: regulation of growth
GO:0008285: negative regulation of cell proliferation
WP3651: Pathways Affected in Adenoid Cystic Carcinoma
GO:1903827: regulation of cellular protein localization
GO:0061564: axon development
M211: PID HEDGEHOG 2PATHWAY
GO:0009611: response to wounding
GO:0042110: T cell activation
GO:0048608: reproductive structure development
GO:0045926: negative regulation of growth
GO:0071363: cellular response to growth factor stimulus
GO:0097190: apoptotic signaling pathway
WP61: Notch Signaling Pathway Netpath
M13: PID ERBB4 PATHWAY
GO:0060541: respiratory system development
GO:0032870: cellular response to hormone stimulus
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Figure 3.4: Characterization of functional enrichment in genes mutated in
human BCC tumors. Metascape analysis of genes that are mutated in human BCC
tumors. Colour scale depicts statistical significance, ranging from lower significance
(orange) to higher significance (dark red).
BCC. Methods including WES, TES, RNA-sequencing can be used to detect the landscape
of heterozygosity and mutations in the genomes of mouse models of BCC to evaluate their
applicability to studying HI. For all experimental designs, there would be at least two
groups of mice — Ptch1+/- mice either exposed to UVB or not. Other modifying factors
or mutagens could be added depending on the research question to study the tumorigenic
potential of the mutation burden. The reported mutation burden and dynamic can be
tracked with UVB exposure and other treatments or preventative measures. Table 3.4
provides a summary of the mutation detection and confirmation methods analyzed to
characterize mouse models of BCC, allowing elucidation of the research questions. All
costs were calculated for 12 samples, two non-UVB exposed mice and four UVB exposed
mice with two technical replicates per sample. This number of samples provides multiple
samples per group to survey the mutation burden in tumors with statistical analysis.
Epidermis samples would be harvested, DNA would be extracted and prepared for
WES. Mouse exome library prep is $337.50 per library prep using Agilent SureSelect mouse
kit plus. To achieve coverage of 150–200X, four exomes can be loaded per sequencing
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Table 3.4: Summary of potential methods for mutation discovery and
confirmation in mouse models of BCC.
Method
Targeted
exome

Application Cost ($)
Detection
63,620.37

Scope
100 genes

Function
Directly confirm reported mutation in human BCC tumors

WES

Detection

12,990.00

All
coding Directly confirm the reported
genes
mutation in human BCC tumors and detect novel variants

RNASequencing

Detection

7,470.00

Transcriptome Determine differentially expressed genes in mouse models

ddPCR

Validation

3,456.00

4 genes

Validate mutations detected in
mouse models

Sanger

Validation

9,483.48

4 genes

Validate mutations detected in
mouse models

lane on a high throughput flow cell. One lane costs $2,980.00; thus, lane costs for 12
samples would be $8,940.00. The total cost for WES of 12 samples is $12,990.00. Data
received would be analyzed using the designed bioinformatic pipeline (Figure 3.5A). First,
data would be processed, including quality control, and aligned to the mouse reference
genome (mm10). Then, the data would be processed and prepared to detect variants and
mutations. Copy number variants and single nucleotide variants would be detected. Data
would be visualized, including a CNV-LP to display the mutation landscape. Mutation
burdens would be compared between groups of mice. Rainfall plots and CNV-LPs would
visualize the single nucleotide variant and copy number variant landscapes in these mice.
Genes with confirmed mutations would be compared to the reported burden in humans
and analyzed using Metascape, PANTHER and KEGG pathway analysis, along with
Gene Ontology enrichment analysis.
Epidermis samples would be harvested, RNA would be extracted and prepared for
RNA-sequencing. Libraries would be prepared using NEBNExt Ultra II Directional RNA
library prep kit, costing $250.00 per sample. Paired sequencing would be done on a

Chapter 3. Mutagenesis in models of BCC

108

HiSeq 2500 instrument. To achieve 360 million paired-end reads, 12 samples can be
run in one and a half sequencing lanes for a total cost of $4,470.00. The total cost for
RNA-sequencing of 12 samples is $7,470.00. Data received would be analyzed using the
designed bioinformatic pipelines (Figure 3.5B). First, data would be assessed for quality
and then aligned to the mouse reference transcriptome. The aligned reads would be
quantified, and then differential expression analysis would be performed. Quality would be
assessed again, and expression data would be visualized using heatmaps and Volcano plots.
Genes that are significantly differentially expressed would be analyzed using Metascape,
PANTHER and KEGG pathway analysis, along with Gene Ontology enrichment analysis.
In addition, genetic variants can be called from RNA-sequencing data using a variant
analysis pipeline [107] or Strelka2 [108]. Data would be visualized, and transcriptomes
would be compared between groups of mice. Both WES and RNA-sequencing pipelines
can be run using Galaxy, R Studio and Python. Different approaches were compared at
each step, and the method that suited this project best was selected [109–113].
Epidermis samples would be harvested, and DNA would be extracted and prepared for
next-generation sequencing (NGS) using a custom panel. An AmpliSeqTM Custom DNA
Panel for Illumina was designed containing 100 genes identified as mutated in human
BCC tumors, either with a strong growth advantage or frequently mutated in human and
mouse BCC (BCC110 panel). Ptch1, Shh, Smo, Tp53, Notch1, Notch2, Gli1, and Gli2
were among the genes included. Data received would be analyzed using the bioinformatics
pipeline applied to WES data. Data would be visualized and compared between groups of
mice. CNV-LP would be used to visualize the mutation burden across the selected genes.
The cost of the Custom DNA panel is $42,186.37, and with consumables and processing
fees, the total comes to $63,620.37.
ddPCR would be performed to confirm the copy number of important genes in BCC
initiation. Epidermis samples would be harvested, DNA would be extracted and prepared
for ddPCR. ddPCR would be performed using six TaqMan Copy Number Assays, selected
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based on the compiled gene database and mutation information: Ptch1 (Mm00400946 cn,
Mm00401581 cn, Mm00400966 cn), Tp53 (Mm00370089 cn), Smo (Mm00735101 cn), and
Rbm10, which acts as a test gene and an internal control on the X chromosome to detect
CNs of 1 (Mm00523229 cn). Considering Ptch1 is the most commonly mutated gene in
BCC, three assays were chosen throughout the gene: one assay overlaps Intron 1 — Exon
1, which must be present and thus is a good candidate to determine if the remaining Ptch1
allele is present (Mm00400946 cn); one assay within exon 9 and the Sterol-sensing domain,
which is reported to be responsible for the inhibition of Smo (Mm00401577 cn); one assay
within exon 16 and the fourth extracellular loop, which is hypothesized to contain the
Shh ligand-binding motif (Mm00400966 cn). One assay was chosen to confirm the copy
number of Smo, another Hh pathway member (Mm00735101 cn). This assay has been
pre-tested and would allow the determination of the CN. One assay was chosen to confirm
the copy number of Tp53, which has been implicated in BCC tumorigenesis [23, 31].
The assay overlaps Exon 1 — Intron 1 and has been previously cited in the literature
(Mm00370089 cn). Finally, one assay was chosen for RNA Binding Motif Protein 10
(Rbm10 ), which is reported to have mutations and can be used as an internal control
(Mm00523229 cn). The total cost of ddPCR would be $3,456.00, including six assays and
consumables.
Sanger sequencing would be performed to confirm mutations in specific genes crucial
to BCC tumorigenesis. Sanger sequencing would be performed to detect mutations in
Ptch1, Tp53, Smo and Rbm10 in 12 mice. The cost per sample is $790.29. The total cost
for 12 samples is $9,483.48. Results would be compared to reference sequences to identify
any variants.
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Figure 3.5: Bioinformatics pipelines to analyze and visualize whole-exome sequencing and RNA-sequencing data.

3.4
3.4.1

Discussion
Reported mutations in BCC and a disparity between human and mouse models

This systematic literature review confirmed the diversity of genes with acquired mutations,
the high mutation burden, and the prevalence of UVB-specific mutations in human BCC
tumors, as previously reported [5, 17, 31]. This chapter presents the first compilation
of genes with mutations in human BCC tumors and the associated research papers.
Additionally, this chapter is the first study to identify and report the striking knowledge
gap between the reported mutations in BCC tumors in humans and mouse BCC models.
It is clear that mouse models of BCC mirror human BCC tumorigenesis and well
represent human BCC tumors in terms of morphology, histology and pathogenesis (Table
3.2) [11, 12, 41, 103]. However, throughout the review, it became apparent that 94%
of mutations have not yet been assayed in mouse models of BCC, with 104 mutations
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reported in human BCC tumors but not mouse tumors. Further, there has been neither
germline nor somatic mutation landscape assessment in mouse BCC tumors. While
there is no argument that the characterization of human BCC tumors is crucial to
understanding BCC, mouse models provide the opportunity to explore mechanisms of
mutagenesis, like HI, carcinogenesis and the tumorigenic and malignant potential of
mutation burdens. Once these models are characterized, researchers can look for evidence
of HI in somatic cells, followed by an exploration of possible HI-associated mutational
mechanisms. Secondary to mechanistic explorations, characterized mouse models of BCC
would be ideal for determining how to modify tumorigenic potential and understand
malignancy to explore interventions toward controlling cancer initiation. Studies using
mouse BCC can potentially provide insights into the complex phenotype seen in the
human eyelid and allow researchers to study this phenotype with varying and controlled
environmental and microenvironmental factors. Confirmation of mutation burden in mice
with and without UVB exposure will allow identification of hotspots and characterization
of the dynamic mutation burden when exposed to UVB.
In addition to the genes known to be important in BCC tumorigenesis being very well
studied [23, 26, 28, 30, 31], researchers have performed whole-exome sequencing on large
groups of human BCC tumor samples to define the mutation landscape [31]. Additional
researchers have performed differential gene expression analysis to create expression profiles
in human BCC tumors [26, 105, 114–117]. A well-characterized mutation landscape and
gene expression profile are crucial for a baseline mutation profile in mouse models of BCC
for any studies going forward, yet no similar research has been carried out in mouse models.
The baseline characterization will allow direct investigation into the phenomenon of HI in
rapidly dividing cells, comparison and further definition of how UVB affects the mutation
burden and gene expression in mice, and provide a model to analyze how other carcinogens
affect the mutation burden in this model. It will also allow studies to determine the
tumorigenic or metastatic potential of a mutation burden and if preventative methods or
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treatments affect either the BCC mutation burden or expression profile.
Mouse models used as proxies for other cancer types have been characterized, and the
benefits emphasize the importance of defining mouse models for more informed research
going forward and highlights the need for similar characterization in mouse models of BCC.
Whole exome sequencing has been used to characterize mouse models of non-small-cell
lung cancer, liver cancer, and breast cancer. Non-small-cell lung cancer was induced by
activation of Kras or carcinogenic exposure, and mutational landscapes were compared,
identifying differences in mutation burdens, single nucleotide variants, and copy number
profiles with or without carcinogenic exposure [118]. A recent study characterized the
mutation landscape of carcinogen-induced mouse models of liver cancer, comparing the
mutation burden in carcinogen-exposed and unexposed mouse liver tumors to each other
and the mutation burden in human hepatocellular carcinomas to identify similarities and
differences with and without exposure and between mouse models and human cancer
[119]. Another study compared two mouse models of breast cancer, MMTV-Neu and
MMTV-PyMT, to determine similarities and differences between the mutation landscape
in both. This characterization and comparison allow researchers to determine which
model will better represent the sub-type of breast cancer they are studying [120].
Overall, the systematic review has shown the knowledge gap that must be filled in
mouse models of BCC. It highlights the need to characterize the landscape of genetic
variation in available mouse models of BCC, specifically Ptch+/- mice, in greater depth,
which will allow more informed research to study HI and possible mechanisms and elucidate
the phenotypes and mechanisms behind the highly mutated yet benign nature of BCC.
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Enriched pathways and terms reflect known pathways involved in human BCC tumorigenesis and should be confirmed in mouse models of BCC

Analysis of the gene list showed enrichment in genes involved in ‘Pathways in Cancer,’
‘Hedgehog signalling pathway,’ and ‘Regulation of smoothened pathway.’ Metascape
and the Gene Ontology Resource identified enrichment in genes involved in ‘Negative
regulation of cell proliferation’ and ‘Negative regulation of growth,’ which could play a
role in most BCC tumors’ benign nature. This enrichment seen in human BCC must be
investigated and confirmed in mouse models of BCC to use them as a valid proxy to study
HI and the complex phenotype of mutation burdens and their tumorigenic, malignant or
metastatic potential.
Considering the large number and variety of pathways and GO terms that show
enrichment from the list of genes mutated in human BCC tumors, it is important to
confirm the mutation burden in available mouse models of BCC and determine whether
or not there are a similar dynamic and number of enriched terms in mouse models. Not
only would these results be important to understand complex phenotypes seen in these
mouse models while using them as proxies for human BCC, but these results could be
used to study and better understand why clones with such a high mutation burden and
mutations in known cancer driver genes are benign or undergo cancer initiation but
rarely metastasize. Previous studies have confirmed that mouse models of BCC share
similar morphologies with human BCC tumors [41, 44, 45, 55]. However, it is essential to
confirm in vivo that the mutation burden and dynamics in available mouse models of
BCC represent human BCC tumors.
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Multiple experimental designs provide options to detect
genetic variation in mouse models of BCC depending on
the scope of the research question, budget and samples
available

The ideal method to interrogate the mutation burden in mouse models of BCC depends
on the research question, number of samples available for analysis and budget. Given a
smaller number of samples or a lower budget, WES or RNA-sequencing would be the ideal
method to detect the mutation burden and further characterize mouse models of BCC.
These methods would allow direct comparison of genes mutated in mouse models to human
tumor samples. In addition, the discovery of mutations in genes not reported in human
tumors is possible, along with differentially expressed genes, which are both essential
factors when fully characterizing phenotypes seen in a model. Comparatively, given a
greater number of samples or a higher budget, targeted-exome sequencing provides a highly
sensitive approach for mutation detection to survey driver mutations and characterize
the dynamic subclonal diversity in the epidermal cells. Detecting mutations in different
clones in the epidermal cells will help elucidate how the mutation burden accumulates
and clonal dynamics. This information will provide an extensively characterized mutation
landscape, which is ideal for studying HI when identifying the landscape of heterozygosity
and potentially associated mutations. Knowing the baseline mutation burden with UVB
exposure will allow researchers to account for UVB mutagenesis when assaying the genome
for evidence of HI and HI mechanisms.
Targeted-exome sequencing, WES, and RNA-sequencing each have their advantages
and disadvantages. Targeted-exome sequencing using the BCC110 targeted gene panel
and WES would allow for direct confirmation of genes that had reported mutations in
human BCC tumors in available mouse models of BCC. This confirmation of mutated
genes would fill the missing mutation gap between human and mouse models of BCC.
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Using a targeted gene panel would not allow for discovering new genes that may be
mutated in mouse models of BCC but would be an optimal method to assess a large
number of samples. In contrast, WES allows for the discovery of genes with previously
unreported mutations in BCC tumors.
Currently, no panels are available to detect the somatic mutation burden in human
or mouse BCC tumors, which means this would be the first targeted NGS panel to test
the mutation burden in skin cancers, particularly BCC. Illumina provides eight targeted
NGS panels focusing on genes with known cancer associations (Appendix 3E). These
panels screen between 6 to 500 known driver genes of various cancers or known modifiers
of tumor invasion or aggression. These panels are very effective and helpful in detecting
mutations in a sample, which can better predict the need for preventative measures or
targeted treatments. One of the eight targeted NGS panels is specifically targeted to
detect mutations in six genes known to increase an individual’s risk for hereditary skin
diseases, including PTCH1 and SUFU. The BCC 110 panel would give researchers a
tool to study the mutation burden in BCC tumors to understand factors that modify
tumorigenesis and the aggressive potential of tumors, and give doctors a panel to assess
BCC patients’ mutation burden.
Both targeted-exome sequencing and WES would allow for comparison and characterization of UVB-specific mutations in mouse models. RNA-sequencing would determine
what is differentially expressed with and without UVB exposure or an environmental
modifier, treatment or preventative method. Somatic mutations can be detected from
RNA-sequencing data using a previously reported pipeline [109], which would allow for
another mutation detection method. Targeted-exome sequencing allows for confirmation
of what is reported in humans. It is the most expensive method, whereas WES is less
expensive and allows for confirmation and discovery, past the mutations that have been
reported in human BCC tumors. RNA-sequencing provides a good alternative for detecting gene expression differences and somatic mutations once the known mutation burden
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in mouse models is established. RNA-sequencing is the least expensive method proposed.

3.4.4

With characterization, mouse models of BCC are
promising proxies of high dynamic genetic variation
to study HI in somatic cells

Currently, available mouse models of BCC are not yet a valid proxy to study HI in somatic
cells as levels of genomic heterozygosity and mutations have not been detected. After the
genetic variation and de novo, somatic mutation burden are detected and characterized in
mouse models of BCC, mouse models can be used as proxies to study multiple complex
phenotypes seen in humans. Combined with array comparative genome hybridization to
detect CNVs across the genome of mouse models of BCC, the HI hypothesis could be
assessed within these characterized models. These experiments would indicate whether HI
occurs within the highly variable skin tissue and, more specifically, within somatic cells or
if HI occurs in germ cells and is meiosis related. The results provided by the methods
and pipelines proposed for genetic variation detection can be used to analyze HI.
Not only could mouse models of BCC with characterized landscapes of genetic variation
be used to study HI, but cancer researchers can utilize these models to study other complex
phenotypes. Another complex phenotype is the tumorigenic potential of mutation burdens
in different environments, as seen in UVB-exposed epidermal tissue and esophageal
epidermal tissue, both containing high levels of mutations and mutations in cancerassociated genes yet no transformation [5, 6]. Similarly, characterized mouse models of
BCC can be used to study the perplexing phenomenon seen in human BCC. A wellcharacterized model will facilitate the better evaluation of preventative measures and
targeted therapies for BCC and suppressing tumor recurrence. Finally, elucidating whether
or not HI occurs in rapidly dividing cancer cells will be invaluable to cancer researchers
to understand HI and if heterozygosity breeds more variation.
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Study limitations

The greatest limitation of this study is that there is no in vivo work performed to confirm
or explore the results presented from the systematic literature review. Additionally,
there is currently no direct evidence of a discontinuous landscape of heterozygosity in
mouse models of BCC. Indirect evidence is implied through loss of heterozygosity in
many genes in human BCC tumors [23, 30, 31, 51–54], oncogenes with 55% heterozygous
driver mutations [50], and the fact that specific Ptch1+/- mouse models were crossed with
CD-1 outbred mice when created [55, 56]. These limitations can quickly be assessed and
ameliorated in future research using the methods provided in this chapter for mutation
detection and confirmation.

3.5

Conclusion

This chapter presents the first systematic review to compile BCC tumors’ mutation burden
in humans and mouse models, identifying a gap in knowledge between reported mutations
in humans and mouse models. This chapter highlights the importance of characterizing
these mouse models to begin to fill this knowledge gap and provide a landscape optimal
for studying HI and other complex phenotypes. This chapter contributes two novel
targeted panels to detect the somatic mutation burden in human BCC tumors and
detect common human BCC mutations in BCC mouse models. Additionally, this chapter
provides pipelines and tools for detection, analysis, and visualization of the mutation
burden and transcriptome in BCC mouse models. Multiple methods and pipelines are
proposed for future researchers to confirm the somatic mutation burden in available mouse
models of BCC, ideally in Ptch1+/- mice. The targeted panel provides a sensitive approach
for mutation detection to survey driver mutations and characterize the epidermal cells’
dynamic subclonal diversity.
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Mouse models of BCC with a characterized landscape of genetic variation will be
optimal to study HI in rapidly dividing cells. The results from Arabidopsis and peach
plants indicate that HI may be active throughout meiosis [1, 2], but whether HI occurs
during recombination or replication is unknown. Thus, HI may be occurring during
replication in mitosis as well, and it is imperative to study this in a model of high
somatic variation. Once the landscape of heterozygosity is detected in mouse models
of BCC and genetic variants are characterized, researchers can analyze for evidence
of co-localizing heterozygosity and mutations. If co-localization is detected, possible
mechanisms can be studied. Elucidation of mutation mechanisms may also provide insight
into any contribution HI has to genetic heterogeneity and mutation burden in BCC
tumors. Secondarily, available mouse models of BCC, particularly Ptch1+/- mice, provide
a means to analyze and explore the mystery of one of the highest mutation burdens within
a benign human cancer. Future work must characterize the somatic mutation burden in
these mouse models before analysis of these two phenomena is possible.
Future research can utilize the provided experimental workflow and analysis tool to
fully characterize the mutation burden in BCC mouse models with and without UVB
exposure, filling a critical knowledge gap. These pipelines can additionally be extended
to other mouse models and biological questions.
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Chapter 4.
Conclusions and future directions
This thesis presents preliminary indirect evidence consistent with predictions based on a
phenomenon of Heterozygote Instability (HI) in the analysis of two stocks of outbred mice
and identifies a mouse cancer model suited to the analysis of HI in somatic cells. Both
models, individually and in combination, are powerful tools to test the HI hypothesis of de
novo mutagenesis directly and elucidate the associated mutational mechanisms. Complete
characterization of genetic variation in outbred mice is also valuable to discover genetic
contributions and the missing heritability contributing to complex disease. Complete
characterization of genetic variation in mouse models of BCC is also valuable to elucidate
the nature and burden of somatic mutations and factors other than the genetic variation
that contribute to carcinogenesis, malignancy and metastasis. This thesis highlights the
power of the genetic model and the value in characterizing models fully.
This thesis confirms that outbred mice are better representatives of genetic variation
in the human genome, as previously known, and should be utilized more frequently when
using mouse models as proxies for human genomic diversity and study of contributors
to complex phenotypes. The CNV landscape was detected and visualized in CD-1 and
NMRI mice. In 99 CD-1 and 279 NRMI mice, 4313 and 2629 CNVs were characterized
across the genome, respectively. Size, location, genes affected by CNVs, and copy number
variable regions were catalogued and compared within and between CD-1 and NMRI
mice. Similarities and differences were identified between CNVs reported in inbred mice,
wild-caught mice, wild-derived mice, and humans. Clusters and deserts of heterozygous
SNP loci were identified across the genomes of both outbred mouse stocks. Characterizing
the heterozygous SNP and CNV landscapes in CD-1 and NMRI mice allowed analysis of
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spatial associations possibly implicating associated mutation mechanisms. A potential
association between localized regions of heterozygosity and CNV occurrence was detected
in CD-1 and NMRI mice. Statistical analysis identified a positive correlation between
increasing levels of heterozygosity and proximally associated CNVs. These findings are
consistent with the HI previously shown in Arabidopsis [1] and peach plants [2]. This
thesis confirms the discontinuous heterozygous landscape at SNP loci in CD-1 and NMRI
mice, highlighting these mice as ideal models to study Heterozygote Instability further by
direct testing using a breeding experiment and assay of heterozygosity and CNVs.
Additionally, towards understanding HI and its possible function in somatic mutagenesis, this thesis presented the first systematic literature review to compile all reported
mutations in human BCC tumors and mouse BCC tumors. The disparity between mutation landscapes documented for human BCC tumors compared to mouse models of BCC
was identified. Characterizing available mouse models of BCC will provide ideal models
to study Heterozygote Instability in somatic cells given high genetic diversity, high cell
replication and high de novo mutation burden. Mouse models of BCC allow for elucidation
of the factors and mechanisms behind one of the highest mutation burdens within one
of the most benign human cancers and provide a model of study of mutagenesis in the
context of very high genetic variation. Furthermore, characterization of the mutation
landscape in mouse models of BCC will provide a baseline of mutations in these mice
without any modifiers or mutagens. This baseline will provide a tool for researchers
while interpreting results obtained using these mouse models in terms of potential genetic
variants that may have contributed to phenotypic variation or comparison if testing carcinogens, preventative measures or possible treatments. Different methods for mutation
detection and subsequent mutation confirmation were compared, and three experimental
workflows were provided to characterize the mutation burden in BCC mouse models.
Two methods were proposed for the confirmation of select mutations. In BCC models,
the mutation burden should be characterized with and without UVB exposure to fully
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explore the dynamics of the mutation burden with UVB exposure, comparable to defining
the mutation burden in non-small-cell lung cancer induced by activating mutations or
carcinogen exposure [3]. Overall, this thesis highlights a need for characterization of
mouse models of BCC to optimize them as models of high dynamic genetic variation to
study HI in somatic cells, along with other complex phenotypes, like the phenomenon seen
in BCC tumors, in UVB-exposed epidermal tissue [4] and esophageal epidermal tissue
[5]. Studying HI in mouse models of BCC will allow elucidation of whether HI occurs in
mitosis in somatic cells or meiosis in germ cells, or both.
The ideal model to test HI in germ and somatic cells would be an outbred mouse
model of BCC, specifically a Ptch1+/- CD-1 outbred mouse model. This level of genomic
variation would better represent the human genome than current inbred mouse models of
BCC. Additionally, outbred BCC mouse models would have discontinuous landscapes of
heterozygosity throughout their genome, optimizing their genome to study HI. While this
may seem counterintuitive considering heterosis and hybrid vigor, which is the increased
fitness of the progeny from two diverse parents [6], CD-1 mice specifically have been
used to study multiple cancer types, including BCC, indicating they are susceptible to
tumorigenesis [7, 8]. This outbred background indicates the worth of testing the occurrence
of BCC tumors in a UVB-exposed Ptch1+/- CD-1 outbred mouse model. A controlled
parent-progeny multi-generational study would be performed using Ptch1+/- CD-1 outbred
mice, with samples taken from germline and somatic cells so both inherited and acquired
mutations could be examined in the context of HI. Not only would this combination
provide an ideal heterozygous genomic landscape to explore HI, but it would also allow
examination of potential mechanisms in meiosis, mitosis, recombination, replication,
normal cell division, cancerous cell division, stem cells, oogenesis, spermatogenesis and
embryogenesis. Combining whole-exome sequencing or whole-genome sequencing, proposed
to characterize the genetic variation in mouse models of BCC with genome-wide array
comparative hybridization, would allow for optimal testing of HI. Once evidence indicates
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potential contexts where HI is occurring, repair deficient mice could be used to elucidate
possible mechanisms.
Future studies can use the characterized genome of outbred mice to enrich research
into the variation in diseases, complex phenotypes, and toxicology responses. Future
research must continue to define a profile of heterozygous SNP clusters that are associated
with proximal CNVs. The attributes included in a profile of heterozygosity in the genome
should include the density of clusters, length of clusters, the number of heterozygous
regions per chromosome, and the sequence context of the heterozygosity which will
lead to a better understanding of Heterozygote Instability in germline cells. Controlled
breeding experiments must be performed to track HI through meiosis in male and female
gametes over multiple generations of outbred mice. After characterizing BCC mouse
models, research can explore the mechanisms behind their benign nature yet very high
mutation burden. A well-characterized model with a defined mutation landscape is not
only crucial in exploring new preventative measures and targeted treatments but will be
highly valuable as models of high genetic variation to study complex phenotypes and
mutational mechanisms. Characterized mouse models of BCC are ideal for tracking HI
through mitosis and replication in somatic cells and track mutations in rapidly dividing
cells. Finally, researchers can apply the experimental design and bioinformatics pipeline
provided here to define the mutation landscape of other mouse models of cancer and
diseases. Mouse models offer a controlled environment to study mutational mechanisms.
This thesis suggests an exquisite combination of two mouse models, outbred mice and
mouse models of BCC, plus experimental design and bioinformatics pipelines to investigate
Heterozygote Instability in germ and somatic cells during meiosis, mitosis, and typical
and atypical cell division.
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CD-1
NMRI

43
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Copy Number Statea
Loss/Gainb
0
2+
(2.23) 1 (0.02) 95 (2.21)
0.01
(1.35) 18 (0.06) 360 (1.29)
0.05

CNV Calls
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Values in brackets are normalized by sample count.
Copy number states: full deletion (CN 0) and gain (CN 2+, 2 or more)
b
Total number of losses (CN 0) divided by number of gains (CN 2+)
a
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Appendix 3E: Targeted next-generation sequencing summary for comparison to a BCC-specific targeted
exome panel
NGS Panel

TruSight Tumor 15

Genes
on Panel
(#)
15

Genes in
Common
(#)
6

161

HH Pathway Genes Mutated in BCC
Genes
None

BRAF, ERBB2, KRAS, NRAS, PIK3CA, TP53

28

PTCH1,
SMO

ARID1A, BRAF, CDKN2A, CREBBP, ERBB2,
ERBB4, FGFR3, FBXW7, JAK2, KDR, KNSTRN,
KRAS, MYCN, NOTCH1, NOTCH2, NOTCH3,
NRAS, PIK3CA, PTCH1, PTEN, RAC1, RB1, SMO,
TERT, TP53, SMARCA4, PIK3CA, TSC1

TruSight Cancer Target 94
Genes

9

PTCH1,
SUFU

CDKN2A, HRAS, PTCH1, PTEN, RB1, SUFU,
TP53, RUNX1, WT1

AmpliSeq for Illumina
Cancer Hotspot Panel

52

11

SMO

BRAF, CDKN2A, ERBB2, ERBB4, FBXW7,
FGFR3, HRAS, JAK2, KDR, KRAS, NOTCH1,
NRAS, PIK3CA, PTEN, RB1, SMO, TP53

AmpliSeq for Illumina
Focus Panel

50

17

SMO

BRAF, ERBB2, ERBB4, FGFR3, HRAS, JAK2,
KRAS, MYCN, NRAS, PIK3CA, SMO

TruSight Tumor 170

170

25

PTCH1,
SMO

ARID1A, BRAF, CCND3, CDKN2A, CREBBP,
ERBB2, ERBB4, FBXW7, FGFR3, HRAS, JAK2,
KDR, KRAS, MYCN, NOTCH1, NOTCH2,
NOTCH3, NRAS, PIK3CA, PTCH1, PTEN, RB1,
SMO, TERT, TP53

AmpliSeq for Illumina
Comprehensive Panel v3
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NGS Panel

Genes
on Panel
(#)
AmpliSeq for Illumina 409
Comprehensive Panel

Continued from previous page
Genes in HH Pathway Genes Mutated in BCC
Common Genes
(#)
37
PTCH1,
ARID1A, ASXL1, BRAF, CDKN2A, CREBBP,
SMO, SUFU CSMD3, CTNNA1, DCC, EPHA3, ERBB2, ERBB4,
FBXW7, FGFR3, HRAS, JAK2, KDR, KEAP1,
KRAS, LRP1B, MLL2, MYCN, NOTCH1, NOTCH2,
NRAS, PIK3CA, PTCH1, PTEN RB1, RUNX1,
SMO, SMARCA4, STK36, SUFU, TET2, TSC1,
TP53, WT1

500

58

PTCH1,
ARID1A, BRAF, CASP8, CD274, CCND3,
SMO, SUFU, CDKN1A, CDKN2A, CREBBP, CTNNA1, E2F3,
GLI1
ERBB2, ERBB4, EPHA3, FAT1, FBXW7, FGFR3,
GLI1, GRIN2A, GRM3, HRAS, JAK2, KDM5A,
KDR, KEAP1, KEL, KRAS, LATS1, LATS2,
LRP1B, MAGI2, MLL, MYCN, NOTCH1, NOTCH2,
NOTCH3, NRAS, PIK3CA, PIK3RI, PPP6C,
PREX2, PTCH1, PTEN, RAC1, RB1, RBM10,
RUNX1, SLIT2, SMARCA4, SMO, STAT5B, SUFU,
TET2, TERT, TSC1, TGFBR1, TP53, WT1, YAP1

Skin Cancer NGS Panel

6

3

PTCH1,
SUFU
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CDKN2A, PTCH1, SUFU
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